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ABSTRACT 
 
 
 Calpain is a class of intracellular cytoplasmic cysteine proteases.1 The enzyme 
participates in different intracellular signaling pathways that are mediated by Ca2+.2 
The two major isoforms of calpain universally distributed in most mammalian tissues 
are calpain 1 (µ-calpain) and calpain 2 (m-calpain). The exact in vivo function of the 
enzyme is not clear, but calpain has been implicated in a variety of physiological and 
pathological conditions,3 such as cancer, stroke, cardiac ischaemia, muscular 
dystrophy, cataract and Alzheimer’s disease. Calpain inhibitors are therefore of 
interest as therapeutic agents and as biomedical tools. 
 
 Several potent calpain inhibitors isolated from natural sources as well as 
synthesized in the laboratory have been reported (Chapter 1.4). Unfortunately, most of 
the inhibitors show poor calpain selectivity, metabolic stability and cell permeability. 
In an attempt to discover new calpain inhibitors, structure-based virtual screening of 
the National cancer Institute’s (NCI) led to the identification of diazosulfonamide 1 
(Ki = 1.0 ± 0.02 µM) as a new nonpeptide competitive inhibitor of µ-calpain. Using 1 
as our lead compound, we first explored the structural requirements of the compound 
that are important for potent calpain inhibition of calpain (Chapter 2). Secondly, 
derivatives of 1 were synthesized to test the hypothesis that introduction of an 
electrophilic group for covalent interaction with the catalytic site thiolate group of 
calpain would enhance inhibition of the enzyme. Thirdly, the anti-tumor potential of 
the compounds was determined by screening them against human and mouse 
melanoma cell lines (Chapter 3). Our data showed that the carboxylic acid and the 
thiazole groups of 1 are important for potent inhibition of calpain. It was also found 
that incorporation of electrophilic groups (aldehyde and alpha-ketoamide) into 
derivatives of 1 significantly enhanced µ-calpain inhibition with Ki values ranging 
from 9 nM to 500 nM). Sulfonamide-based peptidomimetic analogue 19 with Ki of 9 
nM was the most potent calpain inhibitor of the series and was over 100-fold more 
potent than the lead diazosulfonamide 1. Five of the compounds inhibited melanoma 
cell growth with GI50 values ranging from 4 µM to 22 µM. Compound 16 was the 
most effective anti-tumor agent (GI50 4µM) of this series.  
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CHAPTER 1. INTRODUCTION 
 
 
1.1 Research Objective 
 
Calpain is a class of intracellular cytoplasmic cysteine proteases1 that 
participates in different intracellular signaling pathways mediated by Ca2+.2 The 
precise in vivo function of calpain is not completely understood but the enzyme has 
attracted considerable attention because of its implication in a number of 
physiological and pathological conditions such as cancer, stroke, and Alzheimer’s 
disease.1, 3 Hence, potent and selective calpain inhibitors are attractive as therapeutic 
agents and as biomedical tools.4 
 
Potent calpain inhibitors have been discovered in the past decade and the most 
potent inhibitors are peptidomimetic compounds such as MDL-281705-8 and 
SJA-6017,9-12 which display calpain inhibitory activities in the nanomolar range. 
Nonpeptide calpain inhibitors have also been published but the calpain inhibitory 
activities of such compounds, unlike the peptidyl inhibitors, are in the micromolar 
range. Nonetheless, nonpeptide calpain inhibitors are still attractive because of their 
high selectivity and metabolic stability.  
 
The problems of current calpain inhibitors are selectivity, cell permeability 
and metabolic stability. Several methods have been used to address the deficiencies. 
Some functional groups, such as benzyloxycarbonyl, sulfonyl, alkanoyl, substituted 
benzoyl, naphthoyl, xanthines,13 and pyridineethanol,9 have been used as N-terminal 
capping groups to improve potency, selectivity and solubility. Different α-ketone 
carbonyl groups have been incorporated at the P1’ position to explore activity.14 
Weakly basic groups have also been introduced at the P1’ position to increase 
solubility.15 However, discovery of calpain inhibitors that incorporate potency, 
selectivity, metabolic stability, and adequate aqueous solubility within the same 
molecule is still a formidable challenge. Recent crystallographic data showing the 
active site structure of calpain with/without calpain inhibitors have made possible the 
development of potent and selective calpain inhibitors. Based on the X-ray crystal 
structure of the µ-calpain, virtual screening of the NCI compound library coupled 
with enzymological evaluation led to the identification of diazosulfonamide 1 (Ki = 
1.0 ± 0.02 µM, Fig. 1) as a new nonpeptide competitive inhibitor of µ-calpain. 
Sulfonamides have long been used as anti-infective agents in humans so this class of 
compounds is a good lead for optimization to afford novel inhibitors of µ-calpain. 
 
 
N N SHO
HOOC
H
N
O
O S
N
1   
Figure 1. Compound 1. 
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Based on the identification of 1, the objectives of this research were to (a) 
determine the structural requirements of diazosulfonamide 1 that are important for 
calpain inhibition as a prelude to the synthesis of novel sulfonamide-based 
peptidomimetic calpain inhibitors; (b) synthesize sulfonamide-based peptidomimetic 
calpain inhibitors; (c) assess the antiproliferative activity of the compounds since 
calpain has been implicated in carcinogenesis. 
 
 
1.2 Overview of the Calpain Family of Cysteine Proteases 
 
  Calpain (EC 3.4.22.17)16,17 is a member of the cysteine protease family, which 
has nucleophilic thiol group at active site. It is named because typical calpain 
possesses a calmodulin-like calcium-binding domain, “cal-”, and a papain-like 
cysteine protease domain, “-pain”.18 Calpain was first observed in the soluble fraction 
of rat brain extracts by Guroff19 in 1964 and requires Ca2+ for activity. Now crystal 
structures of calpain 120 and calpain 221-23 from human are available.  
 
  Numerous isoforms of calpain have been identified, widely distributed from 
mammals to invertebrate, fungi, yeast, and bacteria.17 To date, sixteen different 
calpain isoforms have been identified in mammals21,24 (Table 1) and could be 
classified into two groups, “typical” calpains and “atypical” calpains, based on 
whether or not they possess EF-hand motifs on the carboxyl terminal24,25 (Figure 2). 
Two typical and ubiquitously distributed mammalian calpains are calpain 1 
(µ-calpain), which requires micromolar concentration of calcium for activation in 
vitro, and calpain 2 (m-calpain), which requires millimolar concentrations of 
calcium.18  
 
  Calpain is also found in a wide variety of tissues, including skeletal muscle, 
cardiac muscle, brain, kidney, lung, liver, and adipose tissues.26 The physiological or 
pathological regulation of calpain in these tissues is intricate and not well understood 
but it is acknowledged that calpain can cleave many intracellular signaling and 
structural proteins which play important roles in physiological or pathological 
conditions. Known calpain substrates include cytoskeletal and structural proteins 
(spectrin, microtubule-associated protein-2, tau factor, α-actinin, fodrin, dystrophin, 
tubulin), membrane bound receptors and proteins (EGF receptor, AMPA receptor, 
G-proteins, anion channel), calmodulin binding proteins (calcium pump, inositol 
1,4,5-trisphosphate kinase), myofibrillar proteins (troponin I, troponin T, myosin), 
transcription factors (c-fos, c-jun) and some other important enzymes (protein kinase 
C, 3-hydroxy-3-methylglutaryl-CoA reductase, cAMP-dependent kinase).27,28 The 
roles of the calpain substrates at pathological conditions have been studies but not 
well understood. But calpain has been implicated in muscular dystrophy, cataract, 
stroke, ischaemia, brain trauma, Alzheimer’s disease, diabetes, and cancer.27 As 
calpain is becoming an attractive therapeutic target, identification of calpain inhibitors 
is necessary.  
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Table 1. Human calpain expression profiles and diseases. 
 
 
Name 
 
Typical/Atypical Tissue Expression Diseases 
    
Calpain 1 Typical Ubiquitous Huntington’s disease, cataracts, stroke, muscular dystrophy, 
traumatic brain injury, spinal cord njury, alzheimer, cancer, 
multiple sclerosis, Lou Gehrig’s disease, osteopenia 
Calpain 2 Typical Ubiquitous Cataracts, muscular dystrophy, stroke, spinal cord injury, 
traumatic brain injury, Alzheimer, Parkinson, 
atherosclerosis, multiple sclerosis, Lou Gehrig’s disease, 
cancer, psoriasis 
Calpain 3 Typical Skeletal muscle, lens, retina Limb girdle muscular dystrophy 2A (LGMD2A), cataracts 
Calpain 4 Typical Ubiquitous  
Calpain 5 Atypical Ubiquitous Huntington’s disease polycystic ovarian syndrome,metabolic 
syndrome 
Calpain 6 Atypical Placenta  
Calpain 7 Atypical Ubiquitous Huntington’s disease 
Calpain 8 Typical Stomach mucosa  
Calpain 9 Typical Digestive tract Gastric cancer 
Calpain 10 Atypical Ubiquitous, and tissue specific 
isoforms 
Huntington’s disease, cataracts (?), diabetes mellitus, 
atherosclerosis, metabolic syndrome 
Calpain 11 Typical Testis  
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Table 1 (continued). 
 
 
 
Name 
 
Typical/Atypical Tissue Expression Diseases 
    
Calpain 12 Typical Ubiquitous Alzheimer (?) 
Calpain 13 Typical Testis/lung   
Calpain 14 Atypical Ubiquitous   
Calpain 15 Atypical Ubiquitous CATM (hereditary cataract with microphthalmia) (?) 
Calpain small subunit 2 Typical N.D.   
    
 
N.D. –not determined 
 
 
 
 
 
 
 
           
Sources: (1) Saez, M. E.; Ramirez-Lorca, R.; Moron, F. J.; Ruiz, A. The therapeutic potential of the calpain family: new aspects. Drug Discov 
Today 2006, 11, 917-923.24 Modified with permission from Elsevier Ltd. (2) Carragher, N. O. Calpain inhibition: a therapeutic strategy targeting 
multiple disease states. Curr Pharm Des 2006, 12, 615-638.25 Modified with permission from Bentham Science Publishers Ltd. 
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Figure 2.  Schematic representation of the calpain family members. 
           
Source: Saez, M. E.; Ramirez-Lorca, R.; Moron, F. J.; Ruiz, A. The therapeutic 
potential of the calpain family: new aspects. Drug Discov Today 2006, 11, 917-923.24 
Adapted with permission from Elsevier Ltd. 
 6
  It is important to note that calpain small subunit 2 was named as calpain14.29 
But after finding two new calpain genes, which are named as calpain13 and calpain14, 
old calpain13 was named as calpain15 and calpain small subunit 2 is not 
calpain14.24,25 Not all calpain isoforms have been isolated at protein level, most of 
them have only been identified at the messenger ribonucleic acid (mRNA) level and 
only have predicted protein structure.23 
 
 
1.2.1 Typical Calpains 
 
 Typical calpains, also named as EF-hand subfamily of calpains, include calpain 
1, 2, 3, 4, 8, 9, 11, 12, 13 and calpain small subunit 2. They posses a Ca2+ binding 
EF-hand structure at the carboxy terminus.25 EF-hand structure is a helix-loop-helix, 
calcium binding motif, in which two helices pack together at an angle of 
approximately 90 degrees, separated by a loop region, where calcium binds. The "EF" 
notation for the motif resulted from the structure of parvalbumin, in which the "E" and 
"F" helices were originally identified to form this calcium binding motif. 30 
 
 
1.2.1.1 Calpains 1 and 2 
 
 Calpain 1 and calpain 2, also known as µ-calpain and m-calpain, respectively, 
are the most extensively characterized members of the calpain superfamily. A large 
amount of calpain literature, including inhibitors, structure, and animal assays focus 
on these two isoforms. Both of them are ubiquitously distributed in mammalian cells. 
Calpain 1 requires micromolar concentrations of Ca2+ for activity in vitro whereas 
calpain 2 needs millimolar levels of Ca2+. They function as hetero-dimers consisting 
of a similar large catalytic subunit and a common regulatory subunit (Figure 2). The 
large subunit is distinct for each calpain but the small subunit is identical. Calpain 1 
has the large 82 kDa catalytic subunit and calpain 2 encodes the 80 kDa catalytic 
subunit. Both calpain 1 and calpain 2 associate with the small 28 kDa regulatory 
subunit. Calpain 1 and calpain 2 share approximately 60% sequence homology.25 
 
 The large subunit of calpain 1 and 2 can be sub-divided into four domains (I-IV) 
based on their amino-acid sequence.25 Domain I (amino acids 1-87 in calpain 1 and 
1-76 in calpain 2) is the N-terminal portion of the large subunit and is highly 
conserved between different species.25 However, this region does not share any 
significant sequence homology with any other polypeptide and its precise function 
remains to be determined.25 Domain I also contains the autolysis site and may be 
cleaved during the autolytic activation, which significantly increases sensitivity to 
Ca2+.21 Domain II (amino acids 88-327 in calpain 1 and 77-316 in calpain 2) is the 
catalytic protease domain which contains a catalytic triad (Cys-His-Asn) for substrate 
hydrolysis. The triad is composed of Cysteine (Cys), Histidine (His) and Asparagine 
(Asn) residues. Cys is located at residue 115 for human calpain 1 and 105 for human 
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calpain 2. The crystal structure of calpain 2 shows that domain II can be divided into 
two sub-domains (IIa and IIb) that are spatially separated in the absence of calcium.22 
The active site residue cysteine is located on subdomain IIa whereas histidine and 
asparagine are located on subdomain IIb.25 Domain III (amino acids 328-569 in 
calpain 1 and 317-555 in calpain 2) is the linker between the catalytic domain II and 
the Ca2+-binding domain IV. It does not have obvious sequence homology to any other 
protein21. But it has eight strands of β-sheets with a topology similar to the C2 domain, 
which is found in such proteins as protein kinase C and phospholipase C.21 C2 domain 
can bind phospholipids in a Ca2+-dependent manner and thus domain III is speculated 
to regulate calpain activity by involvement in electrostatic interactions with domain 
II.25 Besides, when Ca2+ binds to domain IV, domain III changes its tertiary structure 
to increase the accessibility of the active site.31 Domain IV (amino acids 570-714 in 
calpain 1 and 556-699 in calpain 2) is a calmodulin-like domain with five EF hand 
motifs. The first four EF hand motifs are thought to act as calcium binding sites while 
the fifth COOH-terminal EF-hand is involved in dimerization with the 28 kDa small 
subunit (calpain 4).25  
 
 
1.2.1.2 Calpain 4 (Calpain Small Subunit 1, capns1) 
 
 Calpain 4 is well known as the small or regulatory subunit of calpains 1 and 2, 
and it is also known as calpain small subunit 1. It is composed of the NH2-terminal 
domain V and the COOH-terminal domain VI.32 Domain V (amino acids 715-781 in 
calpain 1 and 700-767 in calpain 2) is highly rich in glycine residues, containing about 
30% glycine residues, and is referred to as a hydrophobic domain. The function of 
domain V has not yet been elaborated and it may act as a membrane anchor.33 It is 
proposed that anchoring to membrane is a key step in the activation of the enzyme in 
vivo.34,35 Domain VI (amino acids 782-984 in calpain 1 and 768-970 in calpain 2) is 
connected to domain V by a polyproline linker. It has about 50% sequence identity to 
domain IV and also contains five EF hand motifs, the first four of which bind calcium 
ions while the fifth can interact with its counterpart in another calpain molecule to 
form a homodimer or interact with the catalytic domain of calpain 1 or calpain 
2.25,36,37 
 
 
1.2.1.3 Calpain 3 (p94, nCL-1) 
 
 Calpain 3 gene (capn3), named as p94,38 encodes an 821 amino acid protein,39 
which has different sequence with conventional calpain 1 and 2. mRNA expression of 
calpain 3 can be detected. However, calpain 3 protein is hardly detectable because it 
autolyzes rapidly after its translation with an estimated half-life of 27 minutes.38 
Calpain 3 is also known as novel calpain large subunit 1 (nCL-1), because its large 
subunit was different from calpain 1 and 2, and was the first discovered structure 
outside of the conventional calpain 1 and 2.29 
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 Human calpain 3 shows significant sequence homology with the large subunit 
of human calpain 1 and 2, 54% and 51% respectively,40 and can also be divided into 
four similar domains. As calpain 1 and 2, domain II contains the active site Cys, His, 
Asn residues necessary for catalysis. But unlike calpains 1 and 2, calmodulin-like 
calcium-binding domain IV40 does not bind nor interact with domain VI of calpain 4.2  
 
 Besides, calpain 3 is over 100 amino acid residues longer and has three unique 
sequences (NS, IS1 and IS2) compared to the conventional calpain. NS, which is at 
the N-terminal specific region of domain I, is about 60 residues in length and is rich in 
proline (P) residues at the amino terminal end.41 The precise function has not yet been 
clarified but it is believed to play an important role in the overall tertiary structure of 
the enzyme.2 IS1, located in the middle of domain II, has 62 amino acid residues.38 Its 
function has not been elucidated, but may be involved in regulatory activity.42,43 IS2, 
located at the C-terminal of domain III, has 77 amino acid residues.38 It is rich in 
lysine residues at the amino terminal end and possesses a nuclear localization-like 
sequence, which suggests that calpain 3 could play a role in nuclear localization.41 
 
 In muscle, mRNA expression of calpain 3 is at least 10 fold higher than that of 
calpain 1 and 2.38,40,41 A disruption of the calpain 3 gene resulted in limb girdle 
muscular dystrophy type 2A (LGMD2A), suggesting that the protein may have a 
specific role in the physiological functions of the skeletal muscle.44 Three splice 
variants of calpain 3, Lp82, Lp85, and Rt88, have been detected in rat visual system. 
These variants of calpain 3 are believed to be involved in lens development and 
maturation.45-47 
 
 
1.2.1.4 Calpain 8 
 
 Calpain 8, also known as nCL-2 (novel calpain large subunit 2), was found by 
searching rat cDNA libraries of various tissues.29 The mRNA level of calpain 8 is 
predominantly expressed in the stomach, and weak expression is observed in the small 
intestine,2,48 heart and skeletal muscle.2 Like calpain 3, calpain 8 does not associate 
with the small regulatory subunit.49 But calpain 8 does not have the NS, IS1, and IS2 
sequences which is specific for calpain 3. Calpain 8 has high sequence homology to 
the domain structure of conventional calpain.50 The large subunit of calpain 8 is 58% 
homologous to human calpain 1 and 61% homologous to calpain 2.51 Calpain 8 
contains 703 amino acid residues and can also be divided into four domains. Domain 
II, which has over 70% similarity to m- and µ-calpains, is the most conserved. 
Domain IV has four EF-hand structures.  
 
 Calpain 8 can be alternatively splice to give nCL-2’, which contains 381 amino 
acid residues. nCL-2’ has identical large subunit as nCL-2 but two thirds of domain 
III and calcium binding domain IV are missing.29 Therefore, nCL-2’ is assigned to be 
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a member of the non-EF hand subfamily. The mRNA level of both nCL-2 and nCL-2' 
expressed in the stomach are almost equal with calpain 1 and 2. This suggests that 
nCL-2 and nCL-2’ may play an important role in the stomach as conventional 
calpains 1 and 2 in the stomach.48 
 
 
1.2.1.5 Calpain 9 
 
 Calpain 9, also known as nCL-4 (novel calpain large subunit 4), was identified 
by the screening of rat cDNA. It comprises 690 amino acids and is expressed 
predominantly in the digestive organs such as stomach and small intestine, and in the 
uterus.2 It has a total sequence identity of 54% with human calpain 1, 51% with 
human calpain 2, 52% with rat calpain 8, and 55% with human calpain 3 when the NS, 
IS1, and IS2 regions are excluded.48  The expression of calpain 9 is downregulated in 
gastric cancer tissues and cell lines.52 The depletion of calpain 9 by antisense RNA 
results in cell transformation and tumourigenesis in murine NIH 3T3 fibroblasts.53,54 
These indicate that calpain 9 may function as a tumour suppressor. 
 
 
1.2.1.6 Calpain 11 
 
 Calpain 11 was discovered by a search of the protein sequences in the 
commercially available INCYTE EST database. The predicted calpain 11 protein is a 
702 amino acid protein and has a total sequence identity of 58% with chicken 
µ/m-calpain and 54% with human calpain 1.55 Domain II of calpain 11 contains C, H, 
and N amino acids to be a catalytic triad (Cys-His-Asn). Dmain IV has five 
calcium-binding sequences which suggest that calpain 11 could also possess 
calcium-binding ability.55 mRNA analysis of different tissues suggested that the 
highest level of Capn11 is presented in spermatocytes during the later stages of 
meiosis.55,56 Testis-specific calpain 11 could be involved with testis-specific 
transcription factor regulation or germ cell apoptosis.55 
 
 
1.2.1.7 Calpain12 
 
 Calpain 12 was discovered by searching the GenBank mouse EST database 
with protein sequences of known vertebrate calpains.57 Calpain 12 has 720 amino 
acids and predicted sequence has a homology of 40% with calpain 2.57 I t can also be 
divided into four domains (I-IV), similar to conventional calpains. Calpain 12 has 
catalytic domain II and a Ca2+-binding domain IV. Domain II contains C, H, and N 
amino acids to be catalytic triad and domain IV has five calcium-binding sequences. 
RT-PCR analysis has shown that the CAPN12 gene is ubiquitously expressed but the 
highest amounts are found in cortex of the hair follicles.57  
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1.2.1.8 Calpain13 
 
 Calpain 13 is predominantly distributed in testis, like calpain11, and has also 
been detected in the lung.58 The functions and their eventual role in human diseases 
remain unexplored.24 
 
 
1.2.1.9 Calpain Small Subunit 2 (capns2) 
 
 Calpain small subunit 2 is highly homologous (63% ) to small subunit 1 with 
fewer glycine residues in its domain V than small subunit 2.29 Its function is 
unclear.17,24 
  
 
1.2.2 Atypical Calpains 
 
 “Atypical” calpains (calpain 5, 6, 7, 10, 14 and15) do not possess a domain IV 
that contains EF-hand calcium binding sites at their carboxy terminus. It is unclear 
whether the atypical calpains require calcium for activity. 
 
 
1.2.2.1 Calpain 5 (nCL-3, htra-3) 
 
 Calpain 5 (nCL-3, or htra-3) was identified by a search of the GenBank 
database with the amino acid sequence of domain II of human calpain 1.59 Calpain 5 
is named as nCL-329 because it was the third novel large subunit identified. Calpain 5 
is considered as htra-3 because it is the human homologue of tra-3. Domain I-III of 
calpain 5 has 35% similarity with the tra-3, which is a sex determination gene of the 
nematode.59   
 
 The predicted 634 amino acid sequence of calpain 5 has similar large subunits 
with calpains 1 and 2 from domain I to III and has a novel region termed domain T. 
Domain T does not have the conventional EF-hand motifs for Ca2+-binding as found 
in domain IV.2 It is unclear whether calpain 5 is Ca2+-dependent.  
 
 The mRNA of calpain 5 is present in many tissues, but its highest expression is 
in the colon, small intestine, and testes.29 Since the calpain 5 gene is required for 
correct sexual development in hermaphrodites (e.g., nematodes), it is thought that 
calpain 5 plays a role in sex determination and development in humans.59 
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1.2.2.2 Calpain 6 
 
 Calpain 6 was identified by a search of the GenBank database with the amino 
acid sequence of domain II of human calpains 1 and 2.17 It is also known as CAPNX 
because of its location on the X chromosome. 
 
 The predicted amino acid sequence of calpain 6 has a similar domain II with 
calpains 1 and 2. The cDNA of calpain 6 shows that it does not have the active site 
cysteine residue but rather a nonfunctional lysine residue.29 As a result, the protein of 
calpain 6 is predicted to be protolytically inactive.59 The same thing was observed in 
mice. In addition to the absence of cysteine residue, the mouse mRNA of calpain 6 
does not translate an active site His residue in domain II either.49 Calpain 6 has 47% 
homology to calpain 5.17,60 Both calpain 6 and calpain 5 lack the Ca2+ binding domain 
IV, and is replaced with a T-domain. The function of domain T is still unknown. 
 
 The physiological and pathological roles of calpain 6 remain to be determined. 
mRNA of calpain 6 is expressed in skeletal, heart muscles and in specific cells of the 
lung, kidney and various epithelial cell types.56 Out of 50 tissues tested, the highest 
level of calpain 6 mRNA was expressed only in the placenta, which suggests that the 
protein could play a role in the development process.29 Calpain 6 is also speculated to 
play a role in sex determination and development because of its similarity to tra3 and 
calpain 5, and due to its location on human X chromosome.29 
 
 
1.2.2.3 Calpain 7 (PalBH) 
 
 Calpain 7 was identified by a search of the EST database at the National Center 
for Biotechnology Information with nucleic acid and amino acid sequences of known 
vertebrate calpains. Its predicted 813 amino acid protein product61 shares 26-35% 
identity to the rest of the calpain members.17,29,61 and has little homology in domains 
III and I of calpain 1 and 2.29 Domain II of calpain 7, which contains the active site C, 
H, and N residues, is similar with conventional calpains (calpain 1 and 2).61,62 The 
carboxyl terminal domain shows no homology to either the calmodulin-like domain 
IV or to domain T of calpains 5 and 661 but its carboxyl terminal end is homologous to 
the PalB fungal protease that is involved in alkaline ambient pH adaptation in the 
fungus Aspergillus nidulans.29 So calpain 7 is also known as the PalBH (PalB 
homologous domain).  
 
 Calpain 7 appears to be ubiquitously distributed but its exact function is 
unknown. The levels of calpain 7, along with other calpain family members, such as 
calpain 1, 5 and 10, are increased in Huntington’s disease target-tissue culture and 
transgenic mouse models, suggesting that they might contribute to this neurological 
pathology.24 
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1.2.2.4 Calpain 10 
 
 Calpain 10 was discovered and cloned during a search aimed at identifying type 
2 diabetes susceptibility genes.60 The predicted protein sequence contains the catalytic 
triad (C, H, and N) at active site. The C-terminal of calpain 10 does not have EF-hand 
motifs as typical calpains and is homologous to domain T in calpain 5 and 6. 
 
  High mRNA levels of calpain 10 are found in heart, pancreas, brain, liver, and 
kidney. Calpain 10 is thought to play a role in type 2 diabetes.63-66 
 
 
1.2.2.5 Calpain 14 
 
 Calpain14 was reported on 2001 with calpain 13.58 However, the mRNA of 
calpain 14 could not be detected in any of the 76 tissues examined. Radiation hybrid 
mapping localized the gene within a region mapped to 2p21-2p22.58 
 
 
1.2.2.6 Calpain 15 (Sol H) 
 
 A search of the human EST database showed that calpain 15 has 44% sequence 
homologue67 with sol, the embryo-specific Drosophila small optic lobe gene product29 
hence the ubiquitously distributed human calpain 15 is sometimes referred as SolH.29 
 
 The predicted 1086 amino acid protein contains Cys, His, and Asn active site 
residues within a similar domain II region.29 Like Sol, predicted calpain 15 possesses 
five copies of a zinc-finger-like motif in its amino terminal portion67 instead of 
calmodulin-like domain IV.  
 
 Calpain 15 is expressed at low levels in most tissues. its role has not yet been 
fully determined, but calpain 15 gene has been implicated in a chromosomal 
translocation in a family affected by hereditary cataract with microphthalmia 
(CATM).24,68 
 
 
1.3 Calpain and Disease 
 
 
1.3.1 Limb-Girdle Muscular Dystrophy 2A (LGMD2A) 
 
 In 1954, Walton and Nattrass established limb-girdle muscular dystrophy 
(LGMD) as an entity distinct from other muscular dystrophies.69,70 In 1995, the 
European Neuromuscular Centre Workshop established more precise criteria for 
diagnosis and classification of LGMD, grouping the different subtypes according to 
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their genetic characteristics.69 The designation for autosomal-dominant limb-girdle 
dystrophies is now LGMD1, whereas autosomal-recessive forms are LGMD2.69 
Numerous reviews and individual reports suggest that autosomal recessive is much 
more common than autosomal dominant LGMD. Among patients with LGMD2, types 
2A appears to be one of the more common subtypes.69 LGMD2A is an autosomal 
recessive form of the disease in which the muscle specific calpain 3 (also known as 
p94) is the primary cause.44  
 
 The onset of LGMD2A is usually in the second decade of life, although it has 
been documented to occur as early as age 2.5 and as late as age 49.71 The course of 
the disease is slow but progressive, leading to loss of ambulation by approximately 1 
or 2 decades after diagnosis. Scapular winging and hip abductor sparing are two 
common features.71 At the current time, no effective treatment is available to patients 
with LGMD.69 
 
 Inactivating mutations in the calpain 3 gene are responsible for limb-girdle 
muscular dystrophy LGMD2A.72 Genetic quest for the etiologic gene of a cluster of 
LGMD patients in the southern part of the isle of La Réunion led to the initial 
mapping of the disease locus to the gene CAPN3, encoding the calpain 3 protease.71 
There are now over 280 documented distinct pathogenic CAPN3 mutations. These 
CAPN3 mutations span almost the entire length of the CAPN3 gene with no major 
predominant mutations.71 Of interest is the fact that numerous mutations lead to loss 
of calpain 3 protein, indicating that lack of this protease may lead to pathogenic 
consequences.71 
 
 The exact mechanisms involved in the pathogenesis of LGMD2A are still 
unknown. Since calpain 3 is a protease with a potentially broad range of substrates, 
there is a high probability that it is involved in regulating multiple physiological 
processes. This diverse role for calpain 3 means that its absence or mutations in 
CAPN3 can affect many pathways in muscle cells.71 Hypothetical mechanism (Figure 
3) was proposed to explain why the loss of proteolytic capability of calpain 3 might 
lead to cell dysfunction. Mutations in CAPN3 can lead to loss of proteolytic activity 
or loss of titin anchorage. The latter is likely to reduce regulation of proteolytic 
activity or to remove calpain 3 from its substrates. Loss of proteolysis of substrates 
can cause accumulation of proteins that can subsequently be damaged and then 
aggregate. These aggregates can impair proper muscle function and impair growth, 
leading to muscular dystrophy. 
 
 
1.3.2 Diabetes 
 
 Diabetes mellitus is a metabolic disease which is characterized by high blood 
glucose levels because the body does not release or use insulin adequately. If 
untreated, it can lead to blindness, kidney and heart disease, stroke, loss of limbs and  
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Figure 3. Flow chart demonstrating the pathogenic consequences of calpain 3 
deficiency. Mutations in calpain 3 can lead to loss of proteolytic activity or loss of 
titin anchorage. The latter is likely to reduce regulation of proteolytic activity or to 
remove calpain 3 from its substrates. Loss of proteolysis of substrates can cause 
accumulation of proteins that can subsequently become damaged and then aggregate. 
These aggregates can impair proper muscle function and impair growth, leading to 
muscular dystrophy.  
 
 
 
 
 
 
           
Source: Kramerova, I.; Beckmann, J. S.; Spencer, M. Molecular and cellular basis of 
calpainopathy (limb girdle muscular dystrophy type 2A). Biochim Biophys Acta 2007, 
1772, 128-144.71 Adapted with permission from Elsevier Ltd. 
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diabetes, is caused by autoimmune destruction of the β cells of the pancreas, reduced 
life expectancy.60 Type I diabetes mellitus (T1DM), or insulin-dependent 
insulin-producing cells, rendering the pancreas unable to synthesize and secrete 
insulin.73-76 T1DM accounts for approximately 5–10% of all cases of diabetes with the 
major susceptibility gene mapping to the HLA region of chromosome 6.73,77 Type 2 
diabetes mellitus (T2DM), or non-insulin-dependent diabetes mellitus (NIDDM), 
which is characterized by defects in hepatic glucose production, insulin action and 
insulin secretion,60,73 is the most common form of diabetes. T2DM accounts for 
approximately 90% of cases and affecting 10–20% of those over 45 years of age in 
many developed countries.60 It has been predicted that T2DM will affect 215 million 
people worldwide by 2010.73,77 
 
 For both TIDM and T2DM, in most cases, the precise biochemical defects, 
genetic causes and other contributing factors of these diseases are not fully 
elucidated.73 However, it is becoming increasingly clear that members of the calpain 
family are involved in T2DM.73,77  
 
 In 1996, genome-wide scan studies for type 2 diabetes genes carried out in 
Mexican Americans localized a susceptibility gene, designated NIDDM1, at 
2q37.3.60,78 Four years later, positional cloning studies revealed that NIDDM1 was a 
single gene, CAPN10, which encodes the intracellular cysteine protease, calpain 10.77 
This is the first diabetes gene identified through a genome scan.79 More recently 
attention has started to shift to focus on the functional biology of calpain-10 in 
pancreatic β-cells, skeletal muscle and adipocytes.79 
 
 A number of studies have suggested that calpains may be involved in 
T2DM-related pathways.77 Turner described the putative role(s) of calpain 10 in 
T2DM pathways in Figure 4.79  
 
 Knowledge about the role of calpain 10 in diabetes will lead to improved 
diagnosis, treatment and prevention, and thereby could help to reverse the predicted 
rise in the prevalence of this disorder.60 
 
 
1.3.3 Cataract 
 
 Cataract is a clouding of the eye's naturally clear lens.80 According to the World 
Health Organization, cataract is the leading cause of blindness in the world and affects 
nearly 20.5 million Americans age 40 and older.80,81 The exact cause of cataract is 
unclear, but it may be the result of a lifetime of exposure to ultraviolet radiation 
contained in sunlight, or may be related to other lifestyle factors such as cigarette 
smoking, diet, and alcohol consumption.81,82 To date, cataract removal is the most 
common treatment and more than a million such surgeries are performed each year80,82  
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Figure 4. Proposed sites of action for calpain 10 in T2DM-related pathways. (1) The 
internalization of glucose leads to glycolysis and elevated ATP:ADP ratios through the 
action of mitochondria. This action is strongly diminished by calpain inhibition and 
calpain 10 is suggested to act as a regulator of mitochondrial fuel sensing. (2) The 
secretory stimulus is accompanied by cytoskeletal rearrangement, which leads to the 
transport of secretory granules containing insulin to active sites of exocytosis at the 
plasma membrane. In the case of adipocytes and skeletal muscle, this process 
proceeds via the translocation of vesicles containing GLUT4. This process is highly 
sensitive to calpin inhibition, either through the use of inhibitors or specific CAPN10 
antisense nucleotides, and roles for calpain 10 and calpain 1 have been suggested. (3) 
Exocytosis is mediated by a SNARE family of proteins and a specific isoform of 
calpain 10 has been shown to associate with this family. Based on a number of 
evidence, calpain-10 has been proposed to be a pivotal Ca2+-sensor in exocytosis in β 
cells. 
 
 
 
 
           
Source: Harris, F.; Biswas, S.; Singh, J.; Dennison, S.; Phoenix, D. A. Calpains and 
their multiple roles in diabetes mellitus. Ann N Y Acad Sci 2006, 1084, 452-480.77 
Adapted with permission from New York Academy of Sciences. 
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However, surgery is not truly a cure for cataract 83 and the cost of cataract surgery 
limits individuals in many parts of the world. So there is an urgent need for less 
expensive, nonsurgical approaches to cataract treatment.83 Now there are no 
therapeutic agents that can significantly prevent and treat cataract. 
 
 Biochemists are analyzing the formation of cataracts at a molecular level and 
five calpains are known to occur in the lens, including calpain 1,29 Lp85,84 calpain 2,85 
calpain 1086 and Lp82, a lens-specific splice variant of calpain 3.83 If calpain inhibitors 
can be used as anticataractogenic agents, they could be economical nonsurgical agents 
for cataract treatment. Some evidences suggest that calpain inhibitors would be 
beneficial in prevention and treatment of cataract. E64 showed some ability to reduce 
cataract in rodent models.87 E64d, derivative of E64, also prevented induced cataract in 
lens culture models.88,89 SJA6017, a high selective calpain inhibitor, was found to be 
able to prevent both Ca2+-induced nuclear opacity and crystallin proteolysis in a way 
that correlated with its ability to inhibit calpain 2.10,11,83 More recently, SJA6017 has 
been shown to retard calpain-mediated cataractogenesis in porcine lenses90 and 
Lp82-mediated cataractogenesis in rodent lenses.83 
 
 
1.3.4 Cancer 
 
 Association between abnormal calpain activity and tumorigenesis has been 
observed in many studies. Many gene products of oncogenes and tumor suppressor 
genes are substrates of calpain family enzymes, including c-fos, c-jun, p53, pp60src, 
the estrogen receptor and the adhesion molecule integrin.29 Activities of calpain were 
significantly higher in breast cancer tissues, compared with those of normal breast 
tissues54, and were higher in the ER (estrogen receptor )-positive tumors than in 
ER-negative ones.25,29,91 Treatment of ER positive breast cancer cells with the synthetic 
peptide calpain inhibitor calpeptin can inhibit the growth of ER positive breast cancer 
cells but had no effect on growth of ER negative breast cancer cells.25,92 Calpain 
mediated cleavage of NF2 has been proposed as a mechanism that initiates 
tumourigenesis in a subset of schwannomas and meningiomas.93 Calpain also plays a 
positive regulatory role in melanogenesis through modulating the expression of 
tyrosinase.94 The endogenous calpain inhibitor was selectively cytotoxic to human 
tumor cells from lung, bladder, melanoma and chronic myeloid leukemia tissues, in a 
dose-dependent manner, but not cytotoxic to normal human, urothelial, fallopian tube, 
liver and resting white blood cells.95 The inhibitor was also tested in vivo on Wistar 
rats bearing Walker tumors. Treatment with 50 Units/100 g i.p. daily for 5 days caused 
90% tumor regression and necrosis of metastatic foci in the liver and abdomen, 
without toxic side effects.95 
 
 At the molecular level, calpains 1, 2, 6 and 9 are thought to play a role in 
carcinogenesis. High expression levels of calpain 1 mRNA in tissue samples from 
human renal cell carcinoma correlated with metastasis to peripheral lymph nodes 
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suggesting a role for calpain in both carcinogenesis and tumour progression.25,91,96 
Calpain 1 mRNA levels, were also found to be significantly increased in basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC) when compared with normal 
human skin.25,97 In chronic lymphocytic leukaemia (B-CLL) cells, calpain 1 activity 
was found to be significantly elevated when compared with non-malignant cells.25,98 
Antisense-mediated suppression of calpain 2 gene expression reduced the invasion of 
human DU 145 prostate carcinoma cells both in vitro and in vivo.25,99 This study 
provides the first direct evidence that intervention against a single calpain isoform can 
influence tumor cell progression. 
 
 It has been suggested that calpain 6 may be associated with the development of 
uterine sarcoma and uterine malignant mullerian mixed tumors (MMMTs). Although 
the precise effect of increased expression of capn6 need further investigation, but 
calpain 6 may play a role as a novel tumor marker in those diseases.100 
 
 Expression of calpain 9 was downregulated in gastric cancer tissues and cell 
lines25,52 and the depletion of calpain 9 by antisense RNA strategy resulted in cell 
transformation and tumourigenesis in murine NIH 3T3 fibroblasts.25,53,54 These results 
suggest that calpain 9 might be a new type of tumor suppressor. Thus, identification of 
endogenous substrate(s) of calpain 9 might help to define underlying mechanisms in the 
development of gastric cancer. 
 
 
1.3.5 Alzheimer’s Disease 
 
 Alzheimer’s disease (AD) is a brain disorder that seriously affects a person’s 
ability to carry out daily activities, especially among older people. This disease usually 
begins after age 60, and risk goes up with age. About 5 percent of men and women ages 
65 to 74 have AD, and nearly half of those age 85 and older may have the disease. 
While younger people also may get AD, it is much less common. As many as 4.5 
million Americans suffer from AD, according to the data published by NIH in 2006.101 
The etiology of AD is not fully clear. There probably are several factors that affect each 
person differently. Age is the most important known risk factor for AD.101  
 
 Molecular studies have shown that calpain is involved in AD. The two typical 
brain lesions in Alzheimer’s disease are extracellular amyloid plaques, which are 
deposits of β-amyloid peptides, and intracellular neurofibrillar tangles, which are 
composed primarily of the hyperphosphorylated microtubule-associated tau 
protein.17,78 β-Amyloid peptides, the major components of amyloid plaques in the 
brains of AD patients,102 can activate calpains, thereby mediating the cleavage of 
PARP103, an enzyme that is thought to contribute to the pathophysiology of AD by 
inducing neuronal apoptosis.102,104 Calpain is also thought to cleave p35,105 a regulator 
of cyclin-dependent kinase 5 (cdk5) in the CNS, into two proteins, p10 and p25, and 
then the latter activates cdk5.104-106 p25/cdk5 can hyperphosphorylate tau, a substrate 
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for CDK5. The hyperphosphorylated tau protein results in the formation of 
neurofibrillary tangles in AD's brains.78,104 
 
 Both m-calpain and µ-calpain may be involved in Alzheimer’s disease.107,108 
Activated form of m-calpain is increased in the brains of AD patients.109,110 µ-Calpain 
is abnormally activated in AD brain108 and calpastatin, the endogenous inhibitor of 
calpains, is significantly decreased.109,111 These observations suggest the hypothesis 
that inhibition of calpain activity should prevent or retard the evolution of AD.109 
 
 
1.3.6 Ischemia  
 
 Ischemia is an absolute or relative shortage of the blood supply to an organ. 
Calpain is suspected to play a major role in cerebral ischemia (stroke), traumatic brain 
injury (TBI),29,112 and ischemia in heart,27 kidney,113,114 and liver.115 
 
 Cerebral ischemia is an ischemic condition where the brain or parts of the brain 
do not receive enough blood flow to maintain normal neurological function. 
Traumatic brain injury (TBI), also called intracranial injury, or simply head injury, 
occurs when a sudden trauma causes brain damage. Cerebral ischemia and traumatic 
brain injury (TBI) represent the two most common and well-studied manifestations of 
in vivo excitotoxicity. In cerebral ischemia and traumatic brain injury, decreased 
blood flow in brain areas results in increases in presynaptic vesicular glutamate 
release and inhibition of glutamate re-uptake by adjacent astrocytes (Figure 5).29 The 
resultant excessive glutamate overactivates ionotropic glutamate receptors (NMDA, 
AMPA and kainate receptors),29 which allows Na+ and Ca2+ influx, in the postsynaptic 
membrane. The elevated intracellular Na+ level further triggers the opening of 
voltage-gated neuronal Ca2+ channels, and the resultant Ca2+ overload leads to 
activation of several calcium-dependent enzymes, including protein kinase C (PKC), 
calmodulin (CaM)-dependent NO synthase (NOS), protein kinase II (CaMPK-II), 
phospholipase A2 (PLA2), and especially calpain 1 and 2.29,87 A number of 
subcellular targets have been identified as substrates for calpain cleavage in the brain, 
including cytoskeletal proteins, membrane proteins and various other proteins,28 but 
the precise physiological role of calpain is not yet clearly understood. It is 
acknowledged that overactivated calpain could lead to uncontrolled degradation of 
cytoskeletal proteins, cytosolic and nuclear enzymes and, ultimately, neuronal death.29 
Calpain 1 and 2 play a role in disabling the neurons in signal transduction, membrane 
and cytoskeleton integrity and nuclear function.29 Calpain inhibitor I and leupeptin 
can reduce neuronal damage in global ischaemia.116 Calpain inhibitor I and MDL 
28170 can improve neuronal recovery from hypoxia.117,118 MDL 28170 also can 
reduce infarct size even 6 hours after the initiation of ischemia in a rat model of focal 
cerebral ischaemia, showing that calpain activation may be an obligatory, downstream 
event in the ischemic cell death cascade.119-121 Calpain inhibitors AK295 and AK275 
provide significant neuroprotection in ischemia-induced proteolysis.122,123 All these  
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Figure 5.  Calpain 1 and 2 in cerebral ischemia and traumatic brain injury. 
 
 
 
 
 
           
Source: Huang, Y.; Wang, K. K. The calpain family and human disease. Trends Mol 
Med 2001, 7, 355-362.29 Modified with permission from Elsevier Ltd. 
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cases indicate that inhibition of calpain may be a feasible therapy to maintain neuron 
functions.121 
 
 Myocardial infarction is a medical condition that occurs when the blood supply 
to a part of the heart is interrupted. The resulting ischemia or oxygen shortage causes 
damage and potential death of heart tissue. Calpain is activated during myocardial 
ischaemia and calpain inhibitors showed beneficial effects. However, this area is not 
yet clearly understood. E64c was used as a potential protective agent in a dog model 
where acute myocardial infarction was induced by occlusion of the left anterior 
descending artery. The combination of E64c and reperfusion was found to 
significantly reduce infarct size.87 
 
 Ischemia–reperfusion (I/R) injury involves a cascade of events that ultimately 
lead to cellular damage and organ dysfunction. It is one of the most important issues 
to be resolved in liver surgery. The activation of calpain appears essential in 
I/R-induced apoptosis, but cross-talk between calpain and the caspase systems in 
apoptosis remains unclear at present. In addition to calpain and caspases, other 
proteinases such as nuclear serine protease and cathepsin B may also contribute to the 
apoptosis of hepatocytes. In a rat model of hepatic I/R injury, the calpain inhibitor, 
Cbz-Val-Phe methyl ester, inhibited cell necrosis and apoptosis of the sinusoidal 
endothelial cells and hepatocytes, suggesting that calpain may play a role upstream of 
caspases.124  
 
 
1.4 Calpain Inhibitors 
 
 Crystal structures of calpain with inhibitor proved that calpain inhibitors can 
target against the active catalytic site or interact with other allosteric sites of calpain 
that are important in catalytic activation.13,125 Based on different binding position, 
calpain inhibitors can be divided into active site directed calpain inhibitors and 
allosteric inhibitors. 
 
 
1.4.1 Active Site Directed Calpain Inhibitors 
  
 Active site directed calpain inhibitors usually are the peptidomimetic of calpain 
substrate. They are composed of an address region for enzyme recognition and a 
“warhead” for interaction with the active site cysteine residue in enzyme (Figure 6). 
The warhead is an electrophilic group which can react either reversibly or irreversibly 
with the thiol in the cysteine residue of calpain. According to the different interaction 
with the cysteine residue of calpain active site, active site directed calpain inhibitors 
can be sub-divided into irreversible and reversible calpain inhibitors. 
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Figure 6.  Relationship among calpain, substrate and inhibitors. Scissile bond refers 
to the bond in the substrate that is hydrolyzed by the enzyme. The address region of 
calpain inhibitors is region for enzyme recognition. P1, P2 and P3 refer to the side 
chain of different amino acid from the scissile bond to the amino terminal. P’ refers to 
the side chain of different amino acid from the scissile bond to the acid terminal. S1, 
S2 and S2 refer to the binding positions of enzyme in the corresponding to P1, P2 and 
P’ positions of the peptide substrate. 
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1.4.1.1 Irreversible Calpain Inhibitors 
  
 Peptidyl epoxysuccinate calpain inhibitors are a well-studied group of 
irreversible calpain inhibitors. Epoxysuccinyl derivate E-64 (Figure 7), isolated from 
Aspergillus japonicus,25 is used in many publications. It is selective for cysteine 
proteases13 but not cell permeable because of the presence of charged carboxylate and 
guanidinium groups.25 Modification of E64 by esterification of the carboxyl group 
and modification of the guanidinium group to a benzyloxycarbonyl group resulted in a 
cell permeable compound E64d (Figure 7), which has an N-terminal capping with a 
benzyloxycarbonyl group, and can be converted in vivo to its active form E64c 
(Figure 7) by hydrolysis of the ester.25,126 Intraperitoneal injection of E64 prior to 
selenite induced cataract formation in mice can reduce both the frequency and 
severity of cataract formation.25,127 Administration of E64d in vivo can reduce muscle 
degeneration and muscular dystrophy in dystrophic mice and hamster models.25 Also 
a significant neuroprotection by E64d following spinal cord injury in rats has been 
reported.25,128 E64c was reported to significantly reduce ischaemic injury and infarct 
size in a canine model of acute myocardial infarction.25,129 In cultured lenses, E64, 
E64c and E64d can reduce nuclear opacity by calcium ionophore A23187 in a 
concentration-dependent manner, and E64d ,was the most effective.89  
 
 Besides epoxide group, reported warhead replacements of irreversible calpain 
inhibitors are ketomethylenes, methylsulfonium salts, vinyl sulfones, and disulfide 
linkages (Figure 8). Recently published potent selective compounds don’t show these 
functional groups and focused on reversible calpain inhibitors. Irreversible calpain 
inhibitors have high activated electrophilic groups which is difficult to differentiate 
thiol in cysteine protease with other nucleophilic groups in protease (for example, 
hydroxyl group in serine protease) and cause unexpected adverse effects. 
 
 
1.4.1.2 Reversible Calpain Inhibitors 
 
 Reversible calpain inhibitors are derived from natural sources, such as 
calpastatin and leupeptin, and chemical synthesis sources. Functional groups have 
been reported to be warheads are aldehydes, α- ketocarbonyls, and α-keto 
heterocycles in reversible calpain inhibitors. The α-ketocarbonyl compounds include 
α-ketoacids, α-ketoamides,130 α-ketoesters,130 α-diketones, and α-ketophosphorous131 
(Figure 8). Because aldehyde is more electrophilicity, less electrophilic α-keto 
carbonyl compounds are more possible to be selective to calpain over other cystein 
protease. So recent published potent active site directed reversible calpain inhibitors 
are focused on peptidyl aldehydes and peptidyl α-ketoamides.25 Besides, replacing the 
metabolically labile aldehyde moiety with cyclic hemiacetal, for example SNJ-1715 
(Figure 7), could increase potency, aqueous solubility, excellent oral bioavailability, 
and prolonged plasma half-life in rat model.132 
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Figure 7.  Typital calpain inhibitors. 
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Source: Donkor, I. O. A survey of calpain inhibitors. Curr Med Chem 2000, 7, 
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 Calpastatin is an endogenous calpain multiheaded133 inhibitor that specifically 
inhibits both major isoforms of calpain, m- and µ-calpains.13,134,135 It binds and 
inhibits calpain when calcium levels are high, and is released when calcium levels 
fall.135 To date calpastatin is the only inhibitor that is completely specific for 
calpain.135 Calpastatin does not inhibit cysteine proteases, such as papain, cathepsin B, 
bromelin, or ficin, and other proteases such as trypsin, chymotrypsin, plasmin, 
thrombin, pepsin, cathepsin D, or thermolysin.17,136  Calpastatin is well conserved 
with greater than 70% identity across mammalian species. It is encoded by a single 
gene that has no obvious homologues.135 The structure of calpastatin polypeptide 
(Figure 9) contains five domains, four homologous inhibitory domains of 
approximately 140 amino acids each and a unique N-terminal domain, termed domain 
L, with no inhibitory effect.13,133,135 Each inhibitory domain contains three 
well-conserved subdomains, A, B and C.133 Subdomains A and C of calpastatin 
interact at nM affinity with domain IV and domain VI of calpain, respectively.135,137 
While subdomain B interacts weakly with calpain in the absence of its flanking A and 
C regions135 and is thought to bind to the catalytic site of domain II or domain III of 
calpain.138 Each inhibitory domain is capable of inhibiting one calpain molecule,133 so 
it is considered as calpain multiheaded inhibitor. 
 
 Plants are rich sources of calpain inhibitors. Peptidyl aldehyde calpain 
inhibitors, including leupeptin,139 strepin P-1,140 and staccopins P-1 and P-2,141 can 
inactivate calpain by interacting reversibly with the active site thiol of the enzyme, but 
the problems are this inactivation is not selective to calpain and poor cellular 
permeability.13 In addition, Hiwasa and colleagues13,142 isolated damnacanthal, an 
anthraquinone compound, from the root of Morinda critrifolia can also effectively 
inhibit calpain. Some other calpain inhibitors isolated from plants were well 
summaried by Donkor.13 
 
 Although many potent calpain inhibitors have been isolated from natural 
sources, the problems of isolating compounds are selectivity over other cysteine 
proteases, cell permeability, and even metabolic stablility. So the modification of 
compounds was focused on improving these disadvantages.  
 
 Peptidyl aldehydes (Figure 7) are the largest group of calpain inhibitors. They 
can form a hemithioacetal intermediate by reacting with the active site thiol of the 
calpain catalytic cysteine. The prototypical compound25 of this inhibitor class was 
leupeptin (Figure 7), which was isolated from streptomyces and can enhance neuronal 
survival in gerbils subjected to transient ischaemic injury25,121 and reduce experimental 
spinal cord injury in vivo.25,143 Leupeptin is a potent inhibitor of both µ-calpain and 
m-calpain, but also of plasmin, trypsin, papain, and cathepsin B.13 The other problem 
is that it is not cell permeable because of the positively charged guanidinium group. 
 
 Modification of leupeptin produced a series of representative peptide aldehydes 
(Figure 7) which have greater cell permeability. Tripeptidyl aldehydes, ALLN (calpain  
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Figure 9. Domain structure of human hepatic calpastatin. N = amino terminal 
domain; C = carboxy terminal domain; I, II, III, IV and L = domain; A,B,C = 
subdomain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
Source: Wendt, A.; Thompson, V. F.; Goll, D. E. Interaction of calpastatin with 
calpain: a review. Biol Chem 2004, 385, 465-472.133 Adapted with the permission 
from Walter de Gruyter, Inc. 
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inhibitor 1) and ALLM (calpain inhibitor 2),13,144 have been proven effective as calpain 
inhibitors. ALLN can reduce infarct size and neuronal damage in a rat model of focal 
ischaemia25,116 and attenuate the systemic inflammatory response and multiple organ 
failure mediated by endotoxin in the rat.25,145 ALLN and calpeptin have both been 
shown to reduce vessel restenosis following experimental transluminal angioplasty 
dilation of an atherosclerotic femoral artery in rabbits.25,146 However, ALLN and 
ALLM are not specific for calpain. ALLN is a good inhibitor for cathepsin L (Ki = 0.5 
nM) and ALLM inhibits cathepsin B (Ki = 100 nM).13 
 
 Calpeptin, MDL-28170 and SJA-6017 (Figure 7) are referred to be N-protected 
dipeptidyl aldehydes. Calpeptin is cell permeable and inhibits human platelet calpain 2 
with an IC50 of 40 nM.13 MDL-28170, which is also cell permeable,8,13 can reduce 
neuronal damage in a rat model of cerebral ischemia25,120 and reduce neuronal loss and 
improved locomotor functions in a mouse model of Parkinson’s disease.25,147 Besides, 
pre-injury administration of MDL-28170 in a rat model of diffuse brain injury can 
reduce neuronal injury. Post-injury administration of MDL-28170 by intraspinal 
microinjection in rats can effectively blocked elevation of calpain activity and attenuate 
axonal damage.25 Post-injury administration of SJA-6017 improved neuronal 
functional outcome12,25 in a mouse model of diffuse head injury. In addition, SJA-6017 
showed neuroprotective efficacy via intravenous administration9 in the rat retinal 
ischemia model. But its oral bioavailability was low due to the metabolic lability and 
low water-solubility.9 
 
 Peptidyl α-ketoamides (Figure 7) were found on development of selective 
calpain inhibitors with other peptidyl α-ketone compounds. The α-ketone compounds 
were supposed to reversibly form an enzyme-bound intermediate that results from the 
nucleophilic addition of the catalytic thiol of calpain to the electrophilic ketone of the 
inhibitor.148 Because electrophilicity of α-ketone compounds is less than aldehyde, it 
is thought that α-ketone compounds may be more selective than aldehyde compounds. 
In general α-ketoamides were more effective toward calpain 1 and 2 than 
α-ketoesters,14 so most recently published papers were focused on α-ketoamides 
 
 The early lead inhibitors, mostly aldehyde inhibitors, were hydrophobic and 
therefore poorly soluble in aqueous solutions.148 α-ketoamides were developed to 
improve membrane permeability and the metabolic stability of aldehydes in vivo.14,25 
For example, AK275 (Figure 7) exhibits calpain inhibitory activity (Ki=109nM for 
porcine calpain I) and improved cell permeability.148 AK295 (Figure 7), which has a 
morpholinopropyl group replacing the ethyl group of AK275, significantly improved 
solubility in aqueous solutions.148,149 Both AK29515 and AK275150 provide significant 
neuroprotection against ischemic brain damage. Some other novel α-ketoamide 
derivatives that exhibit calpain inhibitory activity and can suppress neuronal damage in 
models of ischaemic and excitotoxic damage have been reported.25,149,151,152 
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 In order to increase the water solubility, structure modification was going on P3 
position. SNJ-2008 (Figure 7), which has a pyridine group on the P3 position, 
exhibited metabolic stability (about a 12-fold higher retinal AUC than SJA-6017), 
higher water-solubility, and would show retinal efficacy at a lower dose than aldehyde 
lead SJA-6017.9 
 
 An important inhibitor, compound 2 (Figure 7), was reported on 2002,153 This 
naphthalene substituted compound has a Ki of 6nM to human calpain153 and 
represents one of the most potent calpain inhibitors, which are not derived from 
aldehydes. It also showed a moderate selectivity to cathepsin B (15-fold) and 
excellent selectivity to cathepsin L (1000-fold).153 Compound 2 did not block 
non-cysteine proteases even up to higher mM concentrations.153 
 
 
1.4.2 Allosteric Calpain Inhibitors 
 
 Researchers have recently begun to be interested in nonpeptide calpain inhibitors 
(Figure 7). The reason that non-peptide inhibitors are attractive is that they are not 
targeted against the active catalytic site but may interact with other allosteric sites of 
calpain that are important in catalytic activation.25 This makes them selective calpain 
inhibitors over other cysteine proteases, even among the calpain subtypes.  
 
 PD150606 and PD151746 (Ki=0.21 and 0.26µM for µ-calpain, respectively, 
Figure 7) are two α-mercaptoacrylic acid derivatives that are potent, selective and cell 
permeable inhibitors of calpain. X-ray crystal studies revealed that PD150606 inhibit 
calpain by binding to a hydrophobic pocket on domain VI of calpain small subunit.154 
PD151746 even showed approximately 20-fold selectivity for µ-calpain relative to 
m-calpain.25,155 Carboximide derivatives such as quinolinecarboximides (Ki=0.5µM, 
Figure 7) showed significant selectivity and exhibited almost 50-fold more inhibitory 
activity against µ-calpain relative to both cathepsin B and cathepsin L, members of 
cysteine proteases.13,25 The α-mercaptoacrylic acids derivatives are cell-permeable and 
extremely selective for calpain (approximately 600-fold more selective for calpain 
relative to cathepsin B).25 Some other nonpeptide compounds were well summaried by 
Donkor in 2000.13 
 
 
1.4.3 SAR of Current Calpain Inhibitors 
 
 The binding mechanism for most of the nonpeptide calpain inhibitors has yet to 
be elucidated. They may interact with calpain at an allosteric site on the enzyme.25 
Calpain inhibitors targeted against the active catalytic site of calpain usually consist of 
an address region for enzyme recognition and an electrophilic group (warhead) that 
can react with the active site cysteine of the enzyme (Figure 6). In reversible 
inhibitors, the electrophilic group (usually aldehyde or α-keto carbonyl) form reaction 
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intermediates (hemithioacetal or hemithioketal) with the active site thiolate of the 
enzyme, which mimics the mechanism of hydrolysis reaction catalyzed by cysteine 
proteases .156 All the requirements of SAR are summaried in Figure 10. 
 
 
1.4.4.1 P1 Position 
 
 The S1 subsite of calpain can tolerate a wide variety of amino acids at the P1 
position of inhibitors.13 The incorporation of aliphatic (Val, Nle, Leu, Abu, Cha, and 
Met) and aromatic (Phe, Tyr(O-Benzyl)) at the P1 position resulted in compounds with 
good or moderate calpain I inhibitory activity.157 Hydrophobic groups will enhance 
potency while incorporation of amino acids which are capable of hydrogen bonding 
does not increase potency (such as Ser, Thr, Gln and Tyr)157 and is detrimental to 
binding.13 Aromatic amino acids are less potent than aliphatic amino acids.157 No 
substituted group, Gly, is detrimental to activity, compared with Ala.157 
 
 
1.4.4.2 P2 Position 
 
 It was generally thought that the P2 substitute must be either L-valine or 
L-leucine in order to have potent calpain inhibitory activity.13 P2 prefer aliphatic side 
chain and amino acids at P2 which are capable of hydrogen bonding does not increase 
potency.157 Besides acidic or basic amino acids are not beneficial at P2.157 A recent 
study showed that peptides with D-amino acids at P2 postion were also potent calpain 
inhibitors.158,159 Donkor et al. replaced P2 chiral carbon with nitrogen to make it 
urea-based peptidomimetic calpain inhibitors. The compounds mirrored the general 
SAR of peptidyl aldehyde calpain inhibitors and displayed greater selectivity for 
µ-calpain over cathepsin B.3 
 
 
1.4.4.3 N-Terminal Capping  
 
 The N-terminal capping of the calpain inhibitors is one of the most interested 
regions in the development of selective and cellular permeability calpain inhibitors. It 
can tolerate bulky groups and provide an additional recognition element for binding to 
the S3 and S4 subsites of calpain. Polar pyridineethanol9 group was used to increase 
potency and some of pyridineethanol compounds showed a good oral bioavailability. 
Groups used as N-terminal capping agents13 are benzyloxycarbonyl, acetyl, aryl (or 
alkyl) sulfonyl, alkanoyl, substituted benzoyl, naphthoyl, thionaphthalene,13,160 
fluorine, xanthines13,158 and pyridineethanol, Chromone,7 
3,4-dihydro-1,2-benzothiazine 1,1-dioxide ring (Figure 11).161,162 
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Figure 10.  SAR of calpain inhibitors. 
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1.4.4.4 P’ Position 
 
 Li and colleagues14 demonstrated that the S1’ pocket can tolerate a wide variety 
of substitutes including large hydrophobic groups at the P1’ position. Polar 
morpholinopropyl group was also successfully introduced to increase the solubility of 
the compound without affecting activity. 
 
 
1.4.4.5 Amide Hydrogen 
 
 Replacement of P1-P2 amide with ketomethylene isostere could decrease 
calpain inhibitory potency by 250 fold (Figure 12). This suggested that the hydrogen 
bonding between calpain and the P1-P2 amide hydrogen of the inhibitor is important 
for calpain inhibitory potency.163 Donkor et al. showed that Gly271 is the active 
residue of calpain that makes the critical hydrogen bond between the calpain 1 and the 
P1-P2 amide hydrogen.164 Donkor et al. also proved that P1'-P2' amide hydrogen is 
necessary to maintain potency, without it the activity of inhibitor could decrease by 
380 fold (Figure 12).164 Besides, Chaterjee et al.160 and Donkor3 proved that the P2-P3 
amide hydrogen of a calpain inhibitor is not a strict requirement for calpain inhibition. 
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CHAPTER 2. EXPLORATION OF DIAZOSULFONAMIDE DERIVATIVES 
AS CALPAIN INHIBITORS 
 
 
2.1 Structural Requirements Study of Diazosulfonamide 1 
 
 
2.1.1 Objective 
 
 Virtual screening of the NCI compound library led to the identification of 
diazosulfonamide 1 (Figure 1) as a new nonpeptide competitive inhibitor of calpain 1 
(Donkor et al. Unpublished data). Analogs of diazosulfonamide 1 (Figure 13) were 
synthesized to explore the structural requirements of 1 that are important for calpain 
inhibition as a prelude to the synthesis of novel sulfonamide-based peptidomimetic 
calpain inhibitors. 
 
 
2.1.2 Chemistry 
 
 The synthesis of compounds 1 and 5-7 from the corresponding sulfanilamide (8) 
and sulfathiazole (9) is outlined in Scheme 1. The sulfonamides were diazotized using 
NaNO2/HCl to obtain the corresponding diazonium salts, which were treated with 
salicylic acid or 3-hydroxybenzoic acid under basic condition (20% NaOH) to afford 
the target compounds after purification by flash chromatography.  
 
 
2.1.3 Results and Discussion 
 
 Diazosulfonamide 1 was identified by Donkor et al. (unpublished data) to be a 
nonpeptide competitive inhibitor of calpain 1. Figure 14 shows the interaction of the 
compound with active site residues of calpain. The carboxylic acid group of 1 formed 
a hydrogen bond with the NH of the imidazole side chain of His272 while the OH of 
Ser251 formed hydrogen bonds with the nitrogen of the thiazole ring and one of the 
sulfamoyl oxygen atoms of compound 1. A fourth hydrogen bond was formed 
between the other sulfamoyl oxygen and Thr210. 
 
 Analogues of 1 (compounds 5-7 in Figure 13) were synthesized and studied as 
inhibitors of calpain with the goal of exploring the structural requirements of 1 that 
are important for inhibition of the enzyme as a prelude to the synthesis of novel 
sulfonamide-based peptidomimetic calpain inhibitors. The compounds were tested 
against porcine erythrocyte calpain 1 using Suc-Leu-Tyr-AMC as the substrate by 
following the procedure of Donkor et al.165 The calpain inhibitory activity of the 
compounds is shown in Figure 13. Compound 5 was over 60-fold less potent than 1 
suggesting that the hydrogen bonding interaction between the carboxylic acid group  
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Figure 13. Structure and calpain inhibitory activity of compound 1 and its analogues.  
Ki = Inhibitory activity of the compounds versus porcine erythrocyte calpain 1. 
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Scheme 1. Synthesis of compounds 1 and 5-7. 
Reagents: (a) HCl, NaNO2; (b) 20% NaOH. 
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Figure 14. Hydrogen-bonding interactions between calpain 1 and compound 1. 
Hydrogen atoms are removed for clarity, except those involved in hydrogen bonding. 
Hydrogen bonds are shown as black dashed lines. The atoms are colored as follows: 
all the protein residues are orange, except those involved in the hydrogen-bonding 
interactions; carbon = green; hydrogen = cyan; nitrogen = blue; oxygen = red; sulfur = 
yellow. 
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of 1 and His272 is important for calpain inhibition. Reposition of the carboxylic acid 
group meta to the phenolic hydroxyl as 6 led to about a 10-fold decrease in calpain 
inhibition, which further supports the significance of the hydrogen bonding interaction 
or salt bridge formation between the carboxylic acid and His272 to calpain inhibition. 
The thiazole ring, which formed three hydrogen bonds with active site residues, was 
also found to be very important for potent inhibition of calpain because removal of 
this group as in compound 7 resulted in about 55-fold and 6-fold decrease in calpain 
inhibition compared to compounds 1 and 6, respectively.     
 
 
2.1.4 Conclusion 
  
Three analogues of compound 1 were synthesized and studied as inhibitors of 
porcine erythrocyte calpain 1. The compounds inhibited calpain 1 with Ki values 
ranging from 1 µM to 63.2 µM. The thiazole ring and the carboxylic acid substitutes 
of 1 were found to be very important for potent calpain inhibition.  
 
 
2.2 Synthesis of Sulfonamide-Based Peptidomimetic Calpain Inhibitors 
 
 
2.2.1 Objective 
 
Most active site directed calpain inhibitors incorporate an electrophilic 
functionality for covalent interaction with the catalytic site thiolate of the enzyme.13 
This interaction was confirmed for the binding of leupeptin (PDB code 1TL9) and 
E64 (PDB code 1TL0) to engineered calpain 1.125 Compound 1 does not possess an 
electrophilic center for covalent modification of calpain. Due to the significance of 
such an interaction for potent calpain inhibition, we hypothesized that peptidomimetic 
analogues of 1 that incorporate an electrophilic functionality for covalent interaction 
with the catalytic site thiolate residue should be potent inhibitors of calpain. 
Compounds 10-19 (Figure 15) were synthesized as novel sulfonamide-based 
peptidomimetic analogues of 1 to test this hypothesis. Within this series, compounds 
18 and 19 were synthesized as ethylene bridged analgues of diazo derivatives 15 and 
17, respectively, since the diazo group is known to undergo reduction in vivo. 
 
 
2.2.2 Chemistry 
 
 Compounds 10 and 11 were synthesized as shown in Scheme 2. Refluxing 
either 3- or 4-chlorosulfonyl benzoic acid 20 in SOCl2 followed by treating the 
resulting chlorosulfonyl benzoyl chloride with L-phenylalanine methyl ester 
hydrochloride in the presence of DIPEA gave 21, which was reacted with 
2-amino-thiazole in the presence of pyridine to give sulfonamide 22 in 40% overall  
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Figure 15. Sulfonamide-based peptidomimetic compounds 10-19. 
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Scheme 2. Synthesis of compounds 10-12. 
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CH2Cl2, RT, 1 h; (c) 2-Amino-thiazole, Pyridine, RT, 16 h; (d) LiBH4, 5 h; (e) PySO3, 
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yield. Reduction of the ester group of 22 with LiBH4 afforded alcohol 23, which was 
oxidized with PySO3 in DMSO/DCM mixture to give target compounds 10 and 11. 
Ortho substituted derivative 12 was synthesized by reacting 
methyl-(2-chlorosulfonyl)benzoate 24 with 2-amino-thiazole to give 25. Microwave 
assisted coupling of 25 with 2-amino-3-phenylpropanol gave 23, which was 
transformed to aldehyde 12 as described above. 
 
 Dipeptide-sulfonamides 13 and 14 were synthesized as shown in Scheme 3. 
The appropriate chlorosulfonyl benzoic acid 20 was refluxed in SOCl2, treated with 
L-valine methyl ester hydrochloride in the presence of DIPEA followed by reaction 
with 2-amino-thiazole and ester hydrolysis with 1.0 N NaOH to give sulfonamide 27. 
This was coupled with 28, which was synthesized as previously reported by Donkor et 
al166 to give beta-hydroxy ester derivative 29. Oxidation of 29 with PySO3/DMSO 
mixture afforded target compound 13. Attempted hydrolysis of the ester functionality 
of 13 to obtain the α-ketoacid derivative was unsuccessful. Treatment of 29 with 
MeOH/NH3 gave α-hydroxy-β-animo amide derivative 30, which was oxidized with 
PySO3/DMSO mixture to give 14. 
 
 The synthesis of compounds 15-17 is outlined in Scheme 4. Compounds 15 and 
16 were synthesized starting with the commercially available 4-phenylazobenzene 
sulfonyl chloride 31, which was treated with either L-valine methyl ester 
hydrochloride or L-proline methyl ester hydrochloride in the presence of DIPEA to 
give 32 and 33, respectively. Basic hydrolysis of the ester groups of these compounds 
followed by couplying with L-leucinol and oxidation with Dess-Martin reagent gave 
target compounds 15 and 16. The aldehyde 15 was reacted with KCN to give 
cyanohydrin 34 and hydrolysis of the cyano group gave α-hydroxy-β-animo acid ester 
35. Treatment of 35 with MeOH/NH3 gave α-hydroxy-β-animo amide 36, which was 
oxidized with PySO3/DMSO mixture to give 17.  
 
 The synthesis of compounds 18 and 19 is outlined in Scheme 5. The 
compounds were synthesized as described for the synthesis of diazo compounds 15-17. 
4-Styrene sulfonic acid sodium salt 37 was converted to 4-styryl-phenylsulfonic acid 
sodium salt using Heck reaction, which is known to generate products with E 
configuration. We confirmed the geometry of the compounds using 2D C-H 
correlation spectroscopy. Refluxing of the phenylsulfonic acid sodium salt in SOCl2 
gave sulfonyl chloride 38, which was treated with L-valine methyl ester hydrochloride 
in the presence of DIPEA to give sulfonamide 39. Hydrolysis of the ester group of 39 
followed by coupling of the resultant acid with L-leucinol afforded 41, which was 
transformed to aldehyde 18 and alpha-ketoamide 19 as described for the synthesis of 
the corresponding diazo derivatives 15 and 17 in Scheme 4.  
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Scheme 3. Synthesis of dipeptide-sulfonamides 13 and 14. 
Reagents: (a) SOCl2, 1,2-Dichloroethane, Reflux, 1 h; (b) L-Val-OMe.HCl, DIPEA, 
CH2Cl2, RT, 1 h; (c) 2-Amino-thiazole, Pyridine, RT, 16 h; (d) 1.0 N NaOH;  (e) 
HBTU, DIPEA, DMF; (f) 7.0 N NH3 in MeOH, 16 h; (g) PySO3, DMSO, CH2Cl2, RT, 
2 h. 
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Scheme 4. Synthesis of compounds 15-17. 
Reagents: (a) Pyridine, L-Val-OMe.HCl or L-Pro-OMe.HCl, RT, 20 h; (b) 1.0N 
NaOH, MeOH, 55ºC, 2 h; (c) L-leucinol, CDI, THF, CH2Cl2, RT, 96 h; (d) 
Dess-Martin reagent, CH2Cl2; (e) NaHSO3/KCN; (f) con. HCl/MeOH; (g) 7.0N NH3 
in MeOH, 16 h; (g) PySO3, DMSO. 
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Scheme 5. Synthesis of compounds 18-19. 
Reagents: (a) bromobenzene, Pd(OAc)2, TEA, (o-Tol)3P; (b) SOCl2, DMF; (c) 
l-Val-OMe hydrogenchloride, DIPEA, pyridine; (d) 4.0N NaOH, MeOH; (e) 
l-leucinol, TEA, Mukayaima's regaent, DMF; (f) PySO3, DMSO; (g) NaHSO3/KCN; 
(h) con. HCl/MeOH; (i) 7.0N NH3 in MeOH. 
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2.2.3 Results and Discussion 
 
 The sulfonamide-based peptidomimetic compounds 10-19 were synthesized 
and tested as inhibitors of porcine erythrocyte calpain 1 to test the hypothesis that 
derivatives of diazosulfonamide 1 that incorporate an electrophilic group for covalent 
interaction with Cys115 at the active site of calpain would be potent inhibitors of the 
enzyme. Table 2 shows the results of this study. The compounds inhibited calpain 1 
with Ki values ranging from 0.009 µM to 29.8 µM. Structure requirement study of 
compound 1 showed that the thiazole ring is very important for potent calpain 
inhibition. We therefore synthesized compounds 10-14 to determine if appending an 
electrophilic functionality to the phenylsulfathiazole substructure of 1 would result in 
potent calpain inhibition. Compounds 10-12 were designed as pseudo dipeptide 
derivatives while 13 and 14 were designed as pseudo-tripeptide derivatives. Generally, 
the pseudo-tripeptides were more potent calpain inhibitors than the pseudo-dipeptide 
derivatives. Compound 14 with Ki of 62 nM was the most potent member of the series. 
The position of the peptidyl substitute influenced calpain inhibition with the meta 
position (as in 11 and 14) being the most preferred position and the ortho position (as 
in 12) being the least preferred position.  
 
Calpain inhibitors such as MDL28170 were discovered as a result of 
N-terminal capping of dipeptide aldehyde inhibitors of calpain.13 The N-terminal 
capping group occupies the S3/S4 subsites of the enzyme. Compounds 15-17 were 
synthesized to investigate if the N,N’-diphenyl sulfonyl group of compound 1 could 
serve an effective N-terminal capping functionality to enhance calpain inhibition. The 
compounds were potent inhibitors of calpain 1 and displayed Ki values between 16 
nM and 273 nM. Compound 15 with L-valine as the P2 substitutent was more potent 
than 16 with a P2 proline substitutent, which is consistent with previous reports that 
the S2 subsite of calpain prefers small hydrophobic groups at the P2 position of 
inhibitors.13 The alpha-ketoamides 17 and 19 were as potent as the corresponding 
aldehydes 15 and 18, respectively. The diazo bridge of 1 was not involved in 
hydrogen bonding interactions with active site residues (Figure 14). Therefore, we 
hypothesized that replacement of the diazo bridge with an ethylene linker should not 
be detrimental to calpain inhibition. This replacement was inspred by the fact that the 
diazo group of diazosulfonamides (e.g., protosil) is known to undergo reduction in 
vivo. Compounds 18 and 19 were then synthesized as deaza analogues of 15 and 17, 
respectively, and found to be potent inhibitors of calpain with 19 (Ki = 9 nM) being 
the most potent member of all the novel sulfonamide-based peptidomimetic inhibitors 
derived from diazosulfonamide 1. Indeed, compound 19 is one of the most potent 
calpain inhibitors known to date. This compound is especially interesting because it is 
an alpha-ketoamide derivative and so unlike aldehyde calpain inhibitors should not 
undergo oxidation of the critical electrophilic functionality in vivo. Thus, 19 should 
have longer in vivo exposure compared to its aldehyde congener 18 however this 
awaits future pharmacokinetic investigation.  
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Table 2. Inhibition of Porcine Erythrocyte Calpain 1 by Compounds 10-19. 
 
    
Compound aKi (µM) 
    
  
10 4.36 
11 0.5 
12 29.8 
13 8.42 
14 0.062 
15 0.018 
16 0.273 
17 0.016 
18 0.014 
19 0.009 
    
 
aKi values were determined by plotting 1/ν versus I to give intersecting lines with 
correlation coefficient ≥ 0.95. 
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2.2.4 Conclusion 
 
 Sulfonamide-based peptidomimetic compounds 10-19 have been synthesized as 
potent calpain 1 inhibitors. The compounds are hybrid molecules of substructures 
derived from diazosulfonamide 1 and dipeptide aldehyde and dipeptide 
alpha-ketoamides. Introduction of the electrophilic functionality (i.e., the aldehyde 
and alpha-ketoamide) groups significantly enhanced calpain inhibition. 
Sulfonamide-based peptidomimetic analogue 19 with Ki of 9 nM was the most potent 
member of the series. It is twice as potent as MDL28170 (Ki = 20 nM) and over 
100-fold more potent than the lead diazosulfonamide 1.  
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CHAPTER 3.  DETERMINATION OF THE ANTI-TUMOR ACTIVITY OF 
THE SULFONAMIDE-BASED PEPTIDOMIMETIC CALPAIN INHIBITORS 
 
 
3.1 Objective 
 
  Cancer is thought to be deficiency or upregulated function/expression of 
certain functional proteins, which are substrates of various proteolytic enzymes. 
Hence, it is possible to influence a cascade of signal transduction events by regulating 
the activity of a single proteolytic enzyme. As discussed in the introduction (Section 
1.3.4), calpain is one of these proteolytic enzymes and has been implicated a 
molecular target for cancer therapy. Currently, 75% of cancer deaths are due to 
epithelial cancers. The five year survival rates for patients with disseminated 
melanoma is less than 5% with an average survival time of 6-10 months.167 Common 
anticancer drugs, such as taxol, have shown lack of clinical efficacy. Inhibition of 
calpain suppresses cell growth and promotes apoptosis in a variety of human cancer 
cell lines.168-171 Thus, calpain could offer a novel target for the discovery of new 
anticancer agents.  
 
 Although Ki values as determined in cell free system evaluate the intrinsic 
inhibitory potency of compounds, drug effects in whole cell systems are potentially 
confounded by factors including drug stability, cellular penetration and/or 
non-specific binding. To explore the anti-proliferative activities of calpain inhibitors 
in whole cell systems, a selected set of novel sulfonamide analogs and peptidomimetic 
inhibitors were evaluated in human melanoma cell A375 and mouse melanoma cell 
B16F1. Evaluation of the compounds against non-cancer cell line is going on. 
 
 
3.2 Results and Discussion 
 
 Compounds 1, 6, 11, 12 and 15-19 were tested against A375 human melanoma 
cells and mouse B16F1 melanoma cells to explore the anti-proliferative activities of 
calpain inhibitors. Studies were performed according to the protocol described in 
Section 4.3 and the results are summaried in Table 3. Compounds 1, 6, 11 and 12 did 
not show cell growth inhibition at 20 µM. This could be due to poor cell penetration 
and/or weak calpain inhibition. The ClogP values of the compounds ranges from 2 to 
about 3.7. 
 
 Compounds 15-19 showed antiproliferation activity at 20 µM and were selected for 
determination of the concentration required to inhibit melanoma cell growth by 50% 
(i.e., GI50). The compounds displayed moderate antiproliferation activity with GI50 
values ranging from 4 µM to 22 µM. Compound 16 (Figure 15) with proline as the P2  
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Table 3. Structures and Activity of Calpain Inhibitors against Melanoma Cells (A375 
and B16F1) and Porcine Erythrocyte Calpain 1. 
 
     
A375 B16F1 
Compound bGI50± cs.e. (µM) GI50± s.e. (µM) 
dKi (µM) ecLogP
     
     
Taxol 0.009±0.001 0.021±0.0009  
1 a ND 1.0 3.7
6 a ND 9.89 3.1
11 a ND 0.5 2.1
12 a ND 29.8 2.1
15 12.9±1.5 13.7±5.0 0.018 5.5
16 4.1±0.5 13.7±1.7 0.273 4.6
17 22.3±2.1 18.7±3.0 0.016 4.0
18 9.4±2.1 10.3±1.9 0.014 5.7
19 16.0±1.3 17.2±2.8 0.009 4.2
  
 
a = cell growth inhibition <2% at 20µM. 
bGI50 = half maximal growth inhibition 
cs.e.= standard error 
dKi values were determined by Dixon plots using the average of assays and plotting 1/v 
versus I to give intersecting lines with correlation coefficient ≥0.95. 
ecLog P is the calculated partition coefficients of the inhibitors and were 
determined with ChemDraw Ultra ver. 9.0. 
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substitutent was the most effective member of the series for inhibiting the growth of 
the human melanoma cell line A375. Compound 16 with Ki of 273 nM was over 
3-fold more potent than 15 with Ki of 18 nM as inhibitor of A375 cell growth. Thus, 
there appears to be no correlation between calpain inhibition and antiproliferation 
activity of the compounds. However, the compounds were equipotent versus the 
mouse B16F1 cell line. Generally, there was limited variability in the GI50 values of 
the compounds versus the mouse cell line (GI50 10.3 µM to18.7 µM) compared to the 
human cell line (GI50 4.0 µM to 22.3 µM). Compounds 18 and 19 are deaza analogues 
of 15 and 17, respectively. The were more effective against the human A375 cells 
compared to 15 and 17 but were equipotent with these compounds versus the mouse 
melanoma cell line. Compounds 17 and 19 are α-ketoamide analogues of aldehydes 
15 and 18, respectively. Generally, the aldehydes were better antiproliferative agents 
compared to the corresponding α-ketoamides presumably due to their greater 
lipophilicity, which should facilitate cell penetration. Nonetheless, α-ketoamide 17 
and 19 may be more interesting than aldehydes 15 and 18 due to the superior cellular 
stability of the α-ketoamide warhead.  
 
 
3.3 Conclusion 
 
 In this study, we report that the aldehyde and α-ketoamide calpain inhibitors 
showed moderate GI50 values (4 µM to 22 µM) for the growth inhibition of both 
human melanoma cell line A375 and mouse melanoma cell line B16F1. Compound 16 
was the most effective antiproliferative agent (GI50 4 µM) of the series. Compounds 
18 and 19 with an ethylene bridge were better inhibitors of calpain and were also 
better antiproliferative agents than those with the diazo bridge (15 and 17). Besides, 
the ethylene brideg unlike diazo brideg will not undergo reduction in vivo. These 
characters make styrenephenyl group to be excellent group for further studies.  
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CHAPTER 4. EXPERIMENTAL SECTION 
 
 
4.1 General 
 
  All reagents and solvents were purchased from Sigma Aldrich, Fischer 
Scientific, TCI, and Calbiochem, and were used without any further purification. Thin 
layer chromatography (TLC) was performed on silica gel chromatogram plates 
purchased from Analtech, Inc. Fisher silica gel S732-25 (100-400 mesh) was used for 
column chromatography. Melting points were determined on a Fisher-Johns melting 
point apparatus and are uncorrected. Molecular masses were determined with electron 
spray ionization mass spectra (ESI-MS) in Bruker/Hewlett Packard Esquire LC/MS 
instrument. Nuclear magnetic resonance (NMR) spectra for 1H NMR and 13C NMR 
were recorded on Bruker ARX 300 instrument and Varian Inova-500 MHz. 
Deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc. The 
chemical shifts (δ) are reported in parts per million (ppm) relative to TMS, and 
coupling constants (J) were reported in hertz. Splitting patterns were indicated as 
follows: s, singlet; d, doublet; t, triplet; m, multiplet. IR spectra (neat) were recorded 
on a Perkin Elmer precisely Spectrum 100 FT-IR spectrophotometer, and the 
representative absorption bands were reported. Microwave reactions were performed 
on CEM Discover Benchmate. Elemental analyses (C, H, N) were performed by 
Atlantic Microlab Inc., Norcross, GA and are within ± 0.4% of the theoretical values. 
 
 
4.2. Chemistry 
 
 
4.2.1 General Procedure 
 
 General procedure 1. Synthesis of diazosulfonamides. The appropriate 
aromatic amine (6 mmol) was dissolved in a mixture of concentrated HCl (3.4 mL) 
and H2O (14 mL) and diazotized by the dropwise addition of a solution of 17% 
NaNO2 (7.2 mmol) at 0 °C and the mixture was stirred 40 min. Phenol, salicylic acid 
or 3-hydroxy benzoic acid (6 mmol) was dissolved in 20% NaOH (12 mL), cooled to 
0 °C, and a solution of the appropriate aryldiazonium salt was slowly added. The 
resultant colored mixture was stirred for 1 h at 0 °C and the product was precipitated 
by addition of 20% HCl. It was recovered and recrystallized from acetone/water 
mixture.  
 
 General procedure 2. Ester reduction. LiBH4 (40.4 mmol) was carefully 
added carefully to a solution of appropriate ester (21.6 mmol) in anhydrous THF (75 
mL) at -15 °C for 5 min followed by stirring at RT for 0.5-2 h (checked by TLC). 
Excess LiBH4 was destroyed by the dropwise addition of acetone at 0 °C followed by 
extraction with CH2Cl2 and purification of the product by flash chromatography. 
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 General procedure 3. Dess-Martin oxidation. Dess-Martin reagent (17.2 
mmol) was slowly added to an ice cooled solution of the appropriate alcohol (15.6 
mmol) in anhydrous CH2Cl2 (80 mL). After 10 min, the ice bath was removed and the 
milky reaction mixture was stirred at RT for 2-4 h (checked by TLC). A solution of 
Na2S2O3 (160 mmol) in saturated NaHCO3 was added and the mixture was stirred for 
additional 10 min at RT. After separation, the aqueous layer was extracted with 
CH2Cl2 (3 x 30 mL) and the combined organic layer was washed successively with 
NaHCO3 solution, water, and brine followed by drying (MgSO4), concentration, and 
purification either by flash chromatography or crystallization.  
 
 General procedure 4. Pyridine-sulfur trioxide oxidation. A solution of 
PySO3 complex (7.18 mmol) in DMSO (15 mL) was added dropwise to an ice-cooled 
solution of the alcohol (0.798 mmol) and DIPEA (7.36 mmol) in CH2Cl2/DMSO (30 
mL) and the mixture was stirred for 1 h at 0 °C. The reaction mixture was diluted with 
EtOAc (300 mL), washed with aqueous 1N HCl (2 x 30 mL), saturated aqueous 
NaHCO3 (2 x 20 mL), and brine. The organic phase was recovered and dried over 
MgSO4 followed by concentrated and purification either by flash chromatography or 
crystallization. 
 
 
4.2.2 Synthesis of Compounds 1, 5, 6, and 7 
 
 4-((4-Hydroxyphenyl)diazenyl)-N-(thiazol-2-yl)benzenesulfonamide (5). 
Compound 5 was synthesized as described in general procedure 1 as brown solid in 
47% yield. m.p.252-253 ºC. 1H NMR (DMSO-d6) δ 12.8 (s, 1H), 10.44 (s, 1H), 
7.87-7.95 (m, 4H), 7.81 (d, J=9.0, 2H), 7.26 (d, J=4.5, 1H), 6.94 (d, J=9.0, 2H), 6.84 
(d, J=4.5, 1H). MS (ESI) 458.9 [M-H]-. IR (cm-1) 3355 (OH). Anal. Calcd. for: 
C15H12N4O3S2, C, 49.99; H, 3.36; N, 15.55; S, 17.79. Found: C, 49.81; H, 3.37; N, 
15.47; S, 17.75.  
 
 2-Hydroxy-5-((4-(N-thiazol-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid (1) 
Compound 1 was obtained as brown solid in 47.8% yield using the general procedure 
1. m.p.252-254 ºC. 1H NMR (DMSO-d6) δ 12.87 (s, 1H), 8.36 (d, J=2.7, 1H), 8.11 (d, 
J=2.4, 1H), 8.08 (d, J=2.7, 1H), 7.98 (s, 3H), 7.29 (d, J= 4.5, 1H), 7.17 (d, J=4.5, 1H), 
6.87 (d, J=4.8, 1H). MS (ESI) 402.9 [M-H]-. IR (cm-1) 3013 and 3095 (br, OH), 1659 
(C=O). Anal. Calcd. for: C16H12N4O5S2•0.375H2O, C, 46.74; H, 3.13; N, 13.63; S, 
15.60. Found: C, 46.75; H, 3.15; N, 13.61; S, 15.59.  
 
 5-Hydroxy-2-((4-(N-thiazol-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid (6). 
Compound 6 was obtained as brown solid in 40.8% yield as described in general 
procedure 1. m.p.213-214ºC. 1H NMR (DMSO-D6) δ 12.98 (br, 2H), 10.66 (s, 1H), 
7.95 (d, J=8.7, 2H), 7.84 (d, J=8.7, 2H), 7.65 (d, J=8.7, 1H), 7.25 (d, J=4.8, 1H), 
6.97-7.04 (m, 2H), 6.84 (d, J=4.8, 1H). MS (ESI) 402.9 [M-H]-. IR (cm-1) 3339 (OH), 
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1713 (C=O). Anal. Calcd. for: C16H12N4O5S2•0.25 EtOAc. C, 47.88; H, 3.31; N, 13.14; 
S, 15.04. Found: C, 47.59; H, 3.40; N, 13.06; S, 14.87.  
 
 5-Hydroxy-2-((4-sulfamoylphenyl)diazenyl)benzoic acid (7) Compound 7 
was obtained as brown solid in 35.5% yield by following general procedure 1. m.p. 
245-247ºC. 1H NMR (DMSO-d6) δ 7.97 (d, J=8.4, 2H), 7.87 (d, J=8.4, 2H), 7.66 (d, 
J=8.7, 1H), 7.48 (s, 2H), 6.97-7.04 (m, 2H). MS (ESI) 319.8 [M-H]-. IR (cm-1) 3383 
and 3361 (NH), 1717 (C=O). Anal. Calcd. for: C13H11N3O5S, C, 48.60; H, 3.45; N, 
13.08; S, 9.98. Found: C, 48.40; H, 3.49; N, 13.04; S, 9.94. 
 
 
4.2.3 Synthesis of Compounds 10, 11 and 12 
 
 (S)-Methyl 3-phenyl-2-(4-(N-thiazol-2-ylsulfamoyl)benzamido)propanoate 
(22a). 4-Chlorosulfonyl benzoic acid (5.0 g, 22.7 mmol) was dissolved in a mixture of 
SOCl2 (20 mL) and 1,2-dichloroethane (10 mL) and refluxed for 1 h. The solvent was 
removed under vacuum to give a light-brown solid. The solid was dissolved in 
anhydrous CH2Cl2 (25 mL) followed by the addition of L-phenylalanine methyl ester 
hydrochloride (5.14 g, 23.8 mmol) in anhydrous CH2Cl2 (25 mL) containing DIEA 
(4.0 mL) at –20 °C. The mixture was stirred for 30 min at –15 °C to 0 °C and then at 
RT for another 1 h. It was washed with NaHCO3 solution, brine, dried (MgSO4), and 
concentrated to give a solid, which was added to a solution of 2-aminothiazole (3.5 g, 
34.59 mmol) in pyridine (20 mL). After stirring for 17 h, the solution was poured into 
2 N HCl and extracted with EtOAc (3 x 50 mL). The combined extract was washed 
successively with water and brine, dried (MgSO4), concentrated, and purified by flash 
chromatography (acetone/hexane, 4:3) to give a white solid in 40% yield. m.p. 95-99 
°C. 1H NMR (DMSO-d6) δ 12.85 (s, 1H), 9.04 (d, J=7.5, 1H), 7.88 (s, 4H), 7.19-7.28 
(m, 6H), 6.86 (d, J=3.3, 1H), 4.63-4.68 (m, 1H), 3.64 (s, 3H), 3.03-3.21 (m, 2H). MS 
(ESI) 443.9 [M-H]-. IR (cm-1) 3102 (NH), 1736 and 1643 (C=O).  
 
 (S)-N-(1-Hydroxy-3-phenylpropan-2-yl)-4-(N-thiazol-2-ylsulfamoyl)benza-
mide (23a). Compound 22a (3.8 g, 8.5 mmol) was reduced to 23a as described under 
general procedure 2. The crude product was purified by flash chromatography 
(CH2Cl2/acetone, 2:1) to give a white solid in 54.8% yield. m.p. 147-155 °C. 1H NMR 
(DMSO-d6) δ 12.84 (s, 1H), 8.35 (d, J=8.4, 1H), 7.87 (dd, J=8.4, 14.4, 4H), 7.12-7.28 
(m, 6H), 6.86 (d, J=4.5, 1H), 4.85 (t, J=5.4, 1H), 4.10-4.19 (m, 1H), 3.40-3.52 (m, 
2H), 2.94 (dd, J=5.1, 13.8, 1H), 2.77 (dd, J=9.0, 13.8, 1H). MS (ESI) 416.0 [M-H]-. 
IR (cm-1) 3260 and 3104 (NH and OH), 1639 (C=O).  
 
 (S)-N-(1-Oxo-3-phenylpropan-2-yl)-4-(N-thiazol-2-ylsulfamoyl)benzamide 
(10). Oxidation of 23a (1.0 g, 2.4 mmol) with PySO3 complex as described under 
general procedure 4 and purification of the crude product by flash chromatography 
(CH2Cl2/acetone, 2:1) gave 10 as a white solid in 52.25% yield. m.p.103-107 °C. 1H 
NMR (DMSO-d6) δ 12.84 (s, 1H), 9.61 (s, 1H), 9.06 (d, J=7.5, 1H), 7.81-7.94 (m, 
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4H), 7.15-7.30 (m, 6H), 6.86 (d, J=4.5, 1H), 4.50-4.57 (m, 1H), 3.28 (dd, J=5.2, 13.8, 
1H), 2.91 (dd, J=10.5, 13.8, 1H). MS (ESI) 413.9 [M-H]-, 446.0 [M+MeOH-H]-. IR 
(cm-1) 3313 (NH), 1731 and 1642 (C=O). Anal. Calcd. for: C19H17N3O4S2•0.5H2O, C, 
53.76; H, 4.27; N, 9.90; S, 15.11. Found: C, 53.98; H, 4.53; N, 9.58; S, 15.17. 
 
 (S)-Methyl 3-phenyl-2-(3-(N-thiazol-2-ylsulfamoyl)benzamido)propanoate 
(22b) 3-Chlorosulfonyl benzoic acid (7.0 g, 31.7 mmol) was dissolved in a mixture of 
SOCl2 (28 mL) and 1,2-dichloroethane (14 mL) and refluxed for 1.5 h. The solvent 
was removed under vacuum and the residue was dissolved in anhydrous CH2Cl2 (35 
mL) followed by the addition of L-Phe-OMe hydrochloride (7.18 g, 33.3 mmol) in 
anhydrous CH2Cl2 (35 mL) containing DIEA (5.8 mL) at –20 °C. The mixture was 
stirred for 30 min at –15 °C to 0 °C and at RT for another 1 h. The mixture was then 
washed with NaHCO3 solution, brine, and dried (MgSO4). The solvent was removed 
under vacuum and the product was recovered and added to a solution of 
2-aminothiazole (3.49 g, 34.87 mmol) in pyridine (30 mL). After stirring for 17 h at 
RT, the mixture was poured into 2 N HCl and extracted with EtOAc (4 x 70 mL). The 
combined organic layer was washed successively with water and brine, dried 
(MgSO4), concentrated, and purified by flash chromatography (acetone/hexane, 1:1) 
to give a white solid in 41% yield. m.p. 149-152 °C. 1H NMR (acetone-d6) δ 
8.26-8.31 (m, 2H), 8.00 (d, J=7.8, 2H), 7.59 (t, J=7.8, 1H), 7.17-7.34 (m, 6H), 6.81 (d, 
J=4.5, 1H), 4.88-4.95 (m, 1H), 3.69 (s, 3H), 3.29 (dd, J=5.4, 13.8, 1H), 3.16 (dd, 
J=9.3, 13.8, 1H). MS (ESI) 443.9 [M-H]-. IR (cm-1) 3102 (NH), 1738 and 1648 
(C=O). 
 
 (S)-N-(1-Hydroxy-3-phenylpropan-2-yl)-3-(N-thiazol-2-ylsulfamoyl)benza-
mide (23b). Compound 22b (3.2 g, 7.2 mmol) was reduced as described under 
general procedure 2 followed by flash chromatographic purification (acetone/hexane, 
3:2) to give 23b as light yellow in solid 83.37% yield. m.p. 132-140 °C. 1H NMR 
(DMSO-d6) δ 12.80 (s, 1H), 8.47 (d, J=8.4, 1H), 8.22 (s, 1H), 7.98 (d, J=7.8, 1H), 
7.91 (d, J=7.8, 1H), 7.61 (t, J=7.8, 1H), 7.15-7.28 (m, 6H), 6.86 (d, J=4.5, 1H), 4.85 (t, 
J=5.4, 1H), 4.16-4.18 (m, 1H), 3.42-3.54 (m, 3H), 2.95 (dd, J=5.1, 13.8, 1H), 2.79 (dd, 
J=9.3, 13.8, 1H). MS (ESI) 416.0 [M-H]-. IR (cm-1) 3316 (NH and OH), 1637 (C=O). 
 
 (S)-N-(1-Oxo-3-phenylpropan-2-yl)-3-(N-thiazol-2-ylsulfamoyl)benzamide 
(11). Oxidation of 23b (500 mg, 1.199 mmol) with PySO3complex as described under 
general procedure 4 and purification of the crude product by recrystallization from 
acetone/hexane to give 11 as a white solid in 50.6% yield. m.p. 180-182 °C. 1H NMR 
(DMSO-d6) δ 12.81 (s, 1H), 9.62 (s, 1H), 9.18 (d, J=7.5, 1H), 8.26 (t, J=1.5, 1H), 
7.94-8.02 (m, 2H), 7.65 (t, J=7.8, 1H), 7.17-7.29 (m, 6H), 6.87 (d, J=4.5, 1H), 
4.51-4.58 (m, 1H), 2.89-3.27 (m, 2H). MS (ESI) 414.0 [M-H]-. IR (cm-1) 3248 (NH), 
1732 and 1637 (C=O). Anal. Calcd. for: C19H17N3O4S2•0.25H2O, C, 54.34; H, 4.20; N, 
10.00; S, 15.27. Found: C, 54.08; H, 4.38; N, 9.81; S, 15.35. 
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 Methyl 2-(N-thiazol-2-ylsulfamoyl)benzoate (25). Methyl (2-sulfonyl 
chloride) benzoate (4 g, 17.0 mmol) was added to a solution of 2-aminothiazole (1.88 
g, 18.7 mmol) in pyridine (20 mL) and stirred for 100 h at RT followed by heating at 
55 °C for another 2 h. The mixture was poured into 4 N HCl and extracted with 
EtOAc (3 x 25 mL). The combined extract was washed successively with water and 
brine, dried (MgSO4), concentrated, and purified by flash chromatography (ethyl 
acetate/hexane, 3:2) to give a brown solid in 78.7% yield. m.p. 202-205 °C. 1H NMR 
(DMSO-d6) δ 12.78 (s, 1H), 7.91-7.94 (m, 1H), 7.63-6.68 (m, 2H), 7.51-7.54 (m, 1H), 
7.28 (d, J=4.8, 1H), 6.86 (d, J=4.5, 1H), 3.75 (s, 3H). MS (ESI) 321.1 [M+H]+, IR 
(cm-1) 3135 (NH), 1726 (C=O). 
 
 (S)-N-(1-Hydroxy-3-phenylpropan-2-yl)-2-(N-thiazol-2-ylsulfamoyl)benza-
mide (23c). Compound 25 (233 mg, 78.2 mmol) and 2-amino-3-phenyl-propanol (177 
mg, 1.17 mmol) were dissolved in a mixture of DMF (2 mL), 1,4-dioxane (3 mL), and 
2 drops TEA and heated in a microwave at 155 °C, 100 w and 100 psi for 20 min. The 
solvent was removed in vacuo and a few drops of 0.5 N HCl were added followed by 
recrystallization from acetone/hexane to give a light yellow solid in 35.8% yield. m.p. 
99-109 °C. 1H NMR (DMSO-d6) δ 12.63 (s, 1H), 8.02 (d, J=8.4, 1H), 7.88-7.91 (m, 
1H), 7.51-7.61 (m, 2H), 7.14-7.33 (m, 7H), 6.85 (d, J=4.5, 1H), 4.57 (br, 1H), 
4.03-4.12 (m, 1H), 3.39-3.58 (m, 2H), 2.91 (dd, J=6.0, 13.5, 1H), 2.77 (dd, J=8.4, 
13.8, 1H). MS (ESI) 416.0 [M-H]-, 440.1 [M+Na]+. IR (cm-1) 3583, 3419 and 3258 
(NH and OH), 1650 (C=O). 
 
 (S)-N-(1-Oxo-3-phenylpropan-2-yl)-2-(N-thiazol-2-ylsulfamoyl)benzamide 
(12). Oxidation of 23c (460 mg, 1.10 mmol) with PySO3 complex as described under 
general procedure 4 followed by flash chromatographic (ethyl acetate/CH2Cl2, 3:1) 
purification gave 12 as a white solid in 55.16% yield. m.p. 119-121 °C. 1H NMR 
(acetone-d6) δ 9.82 (s, 1H), 7.86-8.21 (m, 2H), 7.18-7.64 (m, 9H), 6.80-7.03 (m, 1H), 
4.50-4.57 (m, 1H), 2.56-3.31 (m, 2H). MS (ESI) 414.1 [M-H]-, 445.9 [M+MeOH-H]-. 
IR (cm-1) 3315 (NH), 1731 (CHO), 1647 (C=O). Anal. Calcd. for: 
C19H17N3O4S2•0.5H2O, C, 53.76; H, 4.27; N, 9.90; S, 15.11. Found: C, 53.55; H, 4.37; 
N, 9.64; S, 15.43. 
 
 
4.2.4 Synthesis of Compounds 13 and 14 
 
 (S)-Methyl 2-(4-(chlorosulfonyl)benzamido)-4-methylpentanoate (26a). A 
solution of 4-chlorosulfonyl benzoic acid (7.0 g, 31.7 mmol) in 1,2-dichloroethane 
(14 mL) and SOCl2 (30 mL) was reflux for 1.5 h and the solvent was removed in 
vacuo to give a light-brown solid. The solid was dissolved in anhydrous CH2Cl2 (40 
mL) followed by the addition of L-leucine methyl ester hydrochloride (8.64 g, 47.59 
mmol) in anhydrous CH2Cl2 (30 mL) containing DIPEA (8.0 mL). The mixture was 
cooled at –20 °C and stirred for 30 min. The temperature was allowed to rise to RT 
and stirred for another 1.5 h. The crude product was purified by column 
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chromatography (ethyl acetate/hexane 1:3) to give a light yellow liquid in 90% yield. 
1H NMR (CDCl3) δ 7.97-8.12 (m, 4H), 6.78 (d, J=8.1, 1H), 4.83-4.89 (m, 1H), 3.80 (s, 
3H), 1.66-1.81 (m, 3H), 1.0 (t, J=5.4, 6H). MS (ESI) 346.2 [M-H]-. IR (cm-1) 1646.75 
(amide), 1740.66 (ester). 
 
 (S)-Methyl 4-methyl-2-(4-(N-thiazol-2-ylsulfamoyl)benzamido)pentanoate 
(27a). 2-Aminothiazole (3.8 g, 38.0 mmol) and K2CO3 (10.5 g, 76.0 mmol) were 
added to a solution of 26a (8.8 g, 25.3 mmol) in dry Acetonitrile (60 mL) and the 
mixture was stirred for 8 h at 75 °C, filtered, and the solvent was removed in vacuo. 
The solid was purified by flash chromatography (acetone/hexane, 3:2) to give a white 
solid in 43.5% yield. m.p. 85-89 ºC. 1H NMR (CDCl3) δ 7.897 (dd, J=8.7, 18.3, 4H), 
7.174 (d, J=6.0, 1H), 6.864 (d, J=8.4, 1H), 6.581 (d, J=6.0, 1H), 4.814-4.887 (m, 1H), 
3.785 (s, 3H), 1.683-1.806 (m, 3H), 0.993 (dd, J=3, 6, 6H). MS (ESI) 410.2[M-H]-. IR 
(cm-1) 16385 (amide), 1737 (ester). 
 
 (3S)-Methyl 2-hydroxy-3-((S)-4-methyl-2-(4-(N-thiazol-2-ylsulfamoyl) 
benzamido)-pentanamido)-4-phenylbutanoate (29a). A mixture of 1.0 N NaOH (30 
mL) and MeOH (10 mL) was added to a solution of 27a (420 mg, 1.02 mmol) in 
CH2Cl2 (50 mL) and stirred at RT for 3 h. The organic solvent was removed and the 
aqueous phase was adjusted to pH 2 with 5.0 N HCl. The solid that separated out was 
recovered and used in the next step without purification. The solid (500 mg, 1.26 
mmol) was dissolved in anhydrous DMF (5 mL) and HBTU (0.45 g, 1.19 mmol) was 
added at 0 ºC. After stirring at RT for 1 h, 28167 (0.29 g, 1.38 mmol) and DIPEA (0.33 
mL) in anhydrous DMF (5 mL) was added and the mixture was stirred for 16 h to 
give a white solid in 44% yield. m.p. 202-204 ºC . 1H NMR (DMSO-d6) δ 8.41 (dd, 
J=8.7, 12.3, 1H), 7.76-7.90 (m, 4H), 7.13-7.20 (m, 5H), 6.99 (d, J=3.9, 1H), 6.53 (d, 
J=3.9, 1H),4.38-4.46 (m, 1H), 4.22-4.30 (m, 1H), 3.99-4.08 (m, 1H), 3.49 (d, 
J=4.8,3H), 2.86 (dd, J=6.0, 13.2, 1H), 2.68 (dd, J=9.0, 13.2, 1H), 1.38-1.54 (m, 2H), 
1.28-1.34 (m, 1H), 0.79-0.90 (m, 6H). MS (ESI) 587.2 [M-H]-. IR (cm-1) 
1647.55(amide), 1737.95 (ester), 3306.25 (NH and OH). 
 
 (S)-Methyl 3-((S)-4-methyl-2-(4-(N-thiazol-2-ylsulfamoyl)benzamido) 
pentanamido)-2-oxo-4-phenylbutanoate (13). Dess-Martin oxidation (general 
procedure 3) of 29a (350 mg, 0.59 mmol) followed by flash chromatographic 
(acetone/hexane, 1:1) purification gave 13 as a white solid in 53.3% yield. m.p. 
118-122 ºC. 1H NMR (CDCl3) δ 12.50 (s, 1H), 7.70-7.78 (m, 4H), 7.52 (d, J=8.4, 1H), 
7.06-7.38 (m, 6H), 6.58 (dd, J=0.9, 4.5, 1H), 5.26-5.36 (m, 1H), 4.72 (dd, J=8.4, 14.1, 
1H), 3.79 (d, J=3.3, 3H), 3.26 (dt, J=5.7, 13.8, 1H), 3.00 (dt, J=8.7, 14.1, 1H), 
1.45-1.74 (m,3H), 0.83-0.94 (m, 6H). MS (ESI) 585.0 [M-H]-. IR (cm-1) 1632 (amide 
and α-ketone), 1732 (ester), 3298 (NH). Anal. Calcd. for: C27H30N4O7S2, C, 55.28; H, 
5.15; N, 9.55; S, 10.93. Found: C, 55.08; H, 5.41; N, 9.36; S, 10.64. 
 
 (S)-Methyl 4-methyl-2-(3-(N-thiazol-2-ylsulfamoyl)benzamido)pentanoate 
(27b). SOCl2 (30 mL) was added to an ice-cooled solution of 3-chlorosulfonyl 
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benzoic acid (7.0 g, 31.7 mmol) in 1,2-dichloroethane (14 mL) at 0 ºC. The mixture 
was allowed to warm to RT and then refluxed for 2 h. The solvent was removed in 
vacuo to give a light-brown liquid, which was dissolved in anhydrous CH2Cl2 (30 mL) 
and L-leucine methylester hydrochloride (8.64 g, 47.59 mmol) in anhydrous CH2Cl2 
(30 mL) containing DIEA (8 mL) was added at –20 ºC. The mixture was stirred for 30 
min. at –15 ºC to 0 ºC and then at RT for 1.5 h. The solvent was removed to give an 
oil (91.8%), which was used in the next step without purification. The oil (6.8 g, 19.6 
mmol) was added to a solution of 2-aminothiazole (1.96 g, 19.6 mmol) in CH2Cl2 (50 
mL) containing anhydrous pyridine (35 mL). The mixture was heated at 40 ºC for 58 
h and the solvent was removed in vacuo. The resulting gummy solid was dissolved in 
EtOAc containing 2 N HCl. The organic phase was separated, washed with 0.5 N HCl, 
brine, and dried (MgSO4). The solvent was evaporated and the residue was purified 
by column chromatography (acetone/hexane, 4:3) to give colorless oil in 44.4% yield. 
1H NMR (CDCl3) δ 8.27 (s, 1H), 7.88 (d, J=7.8, 2H), 7.44 (d, J=7.8, 1H), 7.37 (t, 
J=8.4, 1H), 7.04 (d, J=4.8, 1H), 6.49 (d, J=4.8, 1H), 4.72-4.75 (m, 1H), 3.66 (s, 3H), 
1.64-1.66 (m, 3H), 0.86 (d, J=5.7, 6H). MS (ESI) 410.0 [M-H]-. IR (cm-1) 3298 (NH), 
1744 (C=O). 
 
 (3S)-Methyl 2-hydroxy-3-((S)-4-methyl-2-(3-(N-thiazol-2-ylsulfamoyl) 
benzamido)-pentanamido)-4-phenylbutanoate (29b). NaOH (2.0 N, 75 mL) was 
added to a solution of 27b (3.4 g, 8.27 mmol) in MeOH (150 mL) and the mixture 
was stirred at RT for 1.5 h. The MeOH was removed and the aqueous phase was 
adjusted to pH 2 with 5.0 N HCl to give a light yellow solid (3.0 g), which was used 
without purification. Mukayaima’s reagent (1.79 g, 7.0 mmol) in anhydrous DMF (8 
mL) was added into a stirred ice-cooled solution of above solid (2.54 g, 6.4 mmol), 
28167 (1.21 g, 5.8 mmol) and TEA (2 mL) in anhydrous DMF (11 mL). After stirring at 
RT for 36 h, the solution was poured into H2O (200 mL) and the white solid that 
separated out was recovered by filtration and the filtrate was extracted with EtOAc (3 
x 25 mL). Evaporation of the solvent gave more solid and the combined solids were 
purified by column chromatography (CH2Cl2/MeOH, 20:1) to give a white solid in 
31.9% yield. 1H NMR (acetone-d6) δ 8.39 (t, J=1.5, 1H), 8.09 (dt, J=1.5, 7.8, 1H), 
8.01-8.04 (m, 2H), 7.608 (t, J=7.8, 1H), 7.08-7.36 (m, 6H), 0.79 (d, J=4.5, 1H), 
4.61-4.68 (m, 1H), 4.42-4.51 (m, 1H), 4.15 (d, J=2.4, 1H), 3.56-3.64 (m, 3H), 
1.55-1.73 (m, 3H), 0.82-0.99 (m, 6H). MS (ESI) 587.0 [M-H]-. IR (cm-1) 3317 (NH, 
OH), 1736 and 1639 (C=O).  
 
 N-((2S)-1-((2S)-4-Amino-3-hydroxy-4-oxo-1-phenylbutan-2-ylamino)-4- 
methyl-1-oxopentan-2-yl)-3-(N-thiazol-2-ylsulfamoyl)benzamide (30). Compound 
29b (700 mg, 1.19 mmol) was dissolved in 7.0 N methanolic ammonia (35 mL) and 
stirred at RT for 48 h following which the solvent was removed and the product was 
purified by column chromatography (acetone/hexane/MeOH, 6:2:1) to give a white 
solid in 69.6% yield. m.p. 151-157 ºC. 1H NMR (DMSO-d6) δ 8.68-8.74 (m, 1H), 
8.30 (t, J=1.5, 1H), 8.08 (d, J=7.8, 1H), 8.95 (dt, J=7.8, 0.9, 1H), 7.57-7.71 (m, 2H), 
7.02-7.25 (m, 8H), 6.08 (d, J=4.5, 1H), 5.95 and 5.78 (s, 2:1, 1H), 4.41-4.53 (m, 1H), 
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4.17-4.25 (m,1H), 3.83 and 3.75 (s, 1:2, 1H), 2.80-2.88 (m, 1H), 2.58-2.68 (m, 1H), 
1.34-1.64 (m, 3H), 0.81-0.96 (m, 6H). MS (ESI) 572.1 [M-H]-. IR (cm-1) 3298 (OH 
and NH), 1645 (C=O). 
 
 N-((S)-1-((S)-4-Amino-3,4-dioxo-1-phenylbutan-2-ylamino)-4-methyl-1- 
oxopentan-2-yl)-3-(N-thiazol-2-ylsulfamoyl)benzamide (14). Oxidation of 30 (425 
mg, 0.742 mmol) with pyridine-sulfur trioxide complex as described under general 
procedure 4 followed by flash chromatographic purification (acetone/hexane, 3:2) of 
the crude product gave 14 as a white solid in 54.9% yield. m.p 228-231 ºC. 1H NMR 
(DMSO-d6) δ 12.80 (s, 1H), 8.72 (d, J=8.4, 1H), 8.29-8.35 (m, 2H), 8.06 (t, J=7.8, 
2H), 7.95 (d, J=8.1, 1H), 7.79 (s, 1H), 7.63 (t, J=7.8, 1H), 7.12-7.27 (m, 6H), 6.85 (dd, 
J=1.5, 4.5, 1H), 5.18-5.25 (m, 1H), 4.53-4.60 (m, 1H), 3.11 (dd, J=4.2, 14.4, 1H), 2.83 
(dd, J=9.3, 14.4, 1H), 1.49-1.67 (m, 3H), 0.80-0.91 (m, 6H). MS (ESI) 570.0 [M-H]-. 
IR (cm-1) 3426 and 3276 (NH), 1731, 1674 and 1637 (C=O). Anal. Calcd. for: 
C26H29N5O6S2, C, 54.63; H, 5.16; N, 12.02; S, 11.22.  Found: C, 54.27; H, 5.16; N, 
12.02; S, 10.99 
 
 
4.2.5 Synthesis of Compounds 15-17 
 
 (S)-3-Methyl-2-(4-(phenyldiazenyl)phenylsulfonamido)butanoic acid (32). 
4-Phenyl azobenzenesulfonyl chloride (3 g, 10.69 mmol) was added to a stirred 
ice-cooled solution of L-H-Val-OMe·HCl (2.15 g, 12.8 mmol) in anhydrous pyridine 
(15 mL) and the resulting crimson solution was stirred at RT for 44 h. Following this 
the mixture was poured into 2.0 N HCl (100 mL) and extracted with EtOAc (2 x 60 
mL). The extract was washed successively with 1.0 N HCl, saturated NaHCO3, brine, 
dried (MgSO4), and concentrated. The residue was purified by column 
chromatography (EtOAc/hexane, 1:2) to give 
(S)-Methyl-3-methyl-2-(4-(phenyldiazenyl)phenyl-sulfonamido)butanoate as an 
orange solid in 92.5% yield. m.p. 150-152 ºC. 1H NMR (CDCl3) δ 7.94-8.03 (m, 6H), 
7.53-7.60 (m, 3H), 5.18 (d, J=9.9, 1H), 3.83 (dd, J1=10.2, 5.1, 1H), 3.47 (s, 3H), 
2.04-2.11 (m, 1H), 0.99 (d, J=6.9, 3H), 0.90 (d, J=6.9, 3H). MS (ESI) 374.0 [M-H]-, 
398 [M+Na]+. IR (cm-1) 1736 (ester), 3282 (amide). NaOH (1.0 N, 100 mL) was 
added to a solution of the orange solid (3.3 g, 8.8 mmol) in MeOH (50 mL) and the 
mixture was stirred at 55 ºC for 4 h after which the pH was adjusted to 2 with 2.0 N 
HCl. The solvent was removed and the crude product was recrystallized from 
CH2Cl2/ethyl acetate to give 32 as a yellow solid in 75.5% yield. m.p.220-222 ºC. 1H 
NMR (CDCl3) δ 7.95-8.00 (m, 6H), 7.54-7.59 (3H), 5.17 (d, J=10.2, 1H), 3.87 (dd, 
J=4.5, 9.9, 1H), 2.41 (br, 1H, COOH), 2.07-2.18 (m, 1H), 0.99 (d, J=6.6, 3H), 0.88 (d, 
J=6.6, 3H). MS (ESI) 360.0 [M-H]-, 384.1 [M+Na]+. IR (cm-1) 1694 (C=O), 2876 (br, 
COOH), 3294 (amide). 
 
 (S)-3-Methyl-N-((S)-4-methyl-1-oxopentan-2-yl)-2-(4-(phenyldiazenyl)phe-
nylsulfonamido)-butanamide (15). CDI (494 mg, 3.05 mmol) was added to a stirred 
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ice-cooled solution of 32 (1.0 g, 2.77 mmol) in a mixture of THF (15 mL) and CH2Cl2 
(20 mL). Stirring was continued at RT for 30 min. and L-leucinol (531µL, 4.16mmol) 
was added and the mixture was stirred at RT for 96 h. The solvent was removed and 
the residue was recrystallized from acetone/CH2Cl2 mixture to give 
(S)-N-((S)-1-hydroxy-4-methylpentan-2-yl)-3-methyl-2-(4-(phenyldiazenyl)-phenyl-s
ulfonamido)butanamide as a yellow solid in 51.0% yield. m.p.237-238 ºC. 1H NMR 
(acetone-d6) δ 7.98-8.08 (m, 6H), 7.62-7.68 (m, 3H), 6.98 (d, J=8.1, 1H), 6.52 (d, 
J=8.7, 1H), 3.69-3.81 (m, 3H), 3.36-3.42 (m, 2H), 2.00-2.06 (m, 1H), 1.10-1.19 (m, 
3H), 1.00 (d, J=6.9, 3H), 0.89 (d, J=6.9,3H), 0.69 (d, J=6.0, 3H), 0.64 (d, J=6.0, 3H). 
MS (ESI) 459.0 [M-H]-, 483.3 [M+Na]+. IR (cm-1) 1639 (C=O), 3284 (amide), 3505 
(amide). Dess-Martin oxidation (general procedure 3) of the yellow solid (300 mg, 
0.65 mmol) followed by flash chromatographic purification (acetone /CH2Cl2/hexane, 
2:1:4) gave 15 in 50.2% yield. m.p. 146-149 ºC. 1H NMR (acetone-d6) δ 9.50 and 
9.42 (s, 2:1, 1H)), 7.94-8.10 (m, 6H), 7.54-7.63 (m, 3H), 6.30 and 6.01 (d, 1:2, J=7.2 
and 7.8, 1H), 5.45 and 5.26 (d, 2:1, J=8.7 and 8.1, 1H), 4.40-4.48 (m, 1H), 3.63-3.70 
(m, 1H), 2.09-2.20 (m, 1H), 1.19-1.70 (m, 3H), 0.79-1.01 (m, 12H). MS (ESI) 457.0 
[M-H]-, 513.3 [M+Na+MeOH]+. IR(cm-1) 1715 (CHO), 1668 (C=O). Anal. Calcd. for: 
C23H30N4O4S, C, 60.24; H, 6.59; N, 12.22; S, 6.99.  Found: C, 60.05; H, 6.66; N, 
12.17; S, 6.83. 
 
 (2S)-N-((2S)-1-Cyano-1-hydroxy-4-methylpentan-2-yl)-3-methyl-2-(4- 
(phenyldiazenyl)-phenylsulfonamido)butanamide (34). NaHSO3 (3.2%, 11 mL) 
was added to a solution of 15 (847 mg, 1.85 mmol) in MeOH (30 mL) and stirred at 
RT for 30 h. EtOAc (25 mL) was added followed by 3.2% KCN solution and stirring 
was continued for another 5 h. The EtOAc layer was separated and the aqueous layer 
was extracted twice with EtOAc. The combined organic layer was washed with water, 
brine, and dried (MgSO4). The solvent was removed in vacuo to give an orange solid 
in 90% yield. m.p 93-98 ºC. 1H NMR (CDCl3) δ 7.96-8.04 (m, 6H), 7.56-7.63 (m, 
3H), 6.40-6.53 (m, 1H), 5.43-5.52 (m, 1H), 4.50-4.57 (m, 1H), 4.08-4.24 (m, 1H), 
3.55-3.66 (m, 1H), 2.12-2.24 (m, 1H), 1.40- 1.58 (m, 3H), 0.74-1.00 (m, 12H). MS 
(ESI) 508.1 [M+H]+. IR (cm-1) 3322 (OH), 1659 (C=O) 
 
 (3S)-Methyl-2-hydroxy-5-methyl-3-((S)-3-methyl-2-(4-(phenyldiazenyl) 
phenylsulfonamido)-butanamido)hexanoate (35). Conc. HCl (15 mL) was added to 
a solution of 34 (810 mg, 1.67 mmol) in MeOH (20 mL) and the mixture was stirred 
at 62 ºC for 24 h followed by concentration in vacuo and purification by column 
chromatography (EtOAc/hexane, 1:1) to give an orange solid in 69.4% yield. m.p 
163-168 ºC. 1H NMR (CDCl3) δ 7.95-8.02 (m, 6H), 7.55-7.57 (m, 3H), 5.96 (d, J=9.0, 
1H), 5.57 (d, J=7.8, 1H), 4.22-4.33 (m, 2H), 3.80 (s, 3H), 3.59 (dd, J=4.8, 7.8, 1H), 
2.07-2.15 (m, 1H), 1.04-1.41 (m, 3H), 0.68-0.98 (m, 12H). MS (ESI) 517.0 [M-H]-, 
541.2 [M+Na]+. IR (cm-1) 3522, 3355 and 3270 (NH and OH), 1737 and 1648 (C=O). 
 
 (3S)-2-Hydroxy-5-methyl-3-((S)-3-methyl-2-(4-(phenyldiazenyl)phenylsulf-
onamido)-butanamido)hexanamide (36). Compound 35 (600 mg, 1.15 mmol) was 
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dissolved in 7.0 N methanolic ammonia (30 mL) and stirred at RT for 48 h following 
which the solvent was removed and the product was purified by column 
chromatography (ethyl acetate/hexane, 2:1) to give an orange solid in 68.8% yield. 
m.p 243-248 ºC. 1H NMR (DMSO-d6) δ 7.39-8.06 (m, 11H), 7.03-7.14 (m, 2H), 5.52 
(dd, J=5.7, 15.3, 1H), 3.93-3.96 (m, 1H), 3.64-3.74 (m, 2H), 1.85-1.92 (m, 1H), 
1.23-1.26 (m, 1H), 0.70-1.11 (m, 8H), 0.43-0.63 (m, 6H). MS (ESI) 501.9 [M-H]-, 
526.2 [M+Na]+. IR (cm-1) 3454, 3357 and 3322 (NH and OH), 1668 and 1644 (C=O). 
 
 (1S)-N-((S)-1-Amino-5-methyl-1,2-dioxohexan-3-yl)-2-(4-(phenyldiazenyl) 
phenylsulfonyl)-cyclopentane carboxamide (17). Oxidation of 36 (350 mg, 0.696 
mmol) with pyridine-sulfur trioxide complex as described under general procedure 4 
followed by column chromatographic purification (acetone/hexane 1:1) gave 17 as an 
orange solid in 71.7% yield. m.p. 134-136 ºC. 1H NMR (acetone-d6) δ 7.97-8.09 (m, 
6H), 7.61-7.68 (m, 2H), 7.46 (d, J=6.9, 2H), 6.99 (s, 1H), 6.56 (d, J=9.3, 1H), 
5.03-5.10 (m, 1H), 1.19-1.52 (m, 3H), 1.00 (d, J=6.9, 3H), 0.89 (d, J=6.9, 3H), 0.73 
(dd, J=6.3, 9.3, 6H). MS (ESI) 500.6 [M-H]-. IR (cm-1) 3464, 3360 and 3281 (NH), 
1736 (C=O), 1693 (C=O). Anal. Calcd. for: C24H31N5O5S•0.5H2O, C, 56.45; H, 6.32; 
N, 13.72; S, 6.28.  Found: C, 56.30; H, 6.09; N, 13.59; S, 6.16. 
 
 (1S)-2-(4-(Phenyldiazenyl)phenylsulfonyl)cyclopentanecarboxylic acid (33). 
4-Phenyl azobenzenesulfonyl chloride (5 g, 17.8 mmol) was added to an ice-cooled 
solution of D-Pro-OMe·HCl (3.54 g, 21.3 mmol) in anhydrous pyridine (25 mL) and 
stirred for 20 h at RT after which the mixture was poured into 2.0 N HCl (50 mL) 
solution and extracted with EtOAc (2 x 40 mL). The EtOAc extract was washed 
successively with 2.0 N HCl, saturated NaHCO3, brine, dried (MgSO4), and 
concentrated. The residue was purified by column chromatography (acetone/hexane, 
1:2) to give (1S)-methyl-2-(4-(phenyldiazenyl)phenylsulfonyl) 
cyclopentane carboxylate as a yellow solid in 87.3% yield. m.p. 126-128 ºC . 1H NMR 
(CDCl3) δ 8.04 (s, 4H), 7.95-7.98 (m, 2H), 7.53-7.60 (m, 3H), 4.40 (dd, J=5.6, 6.9, 
1H), 3.73 (s, 3H), 3.52-3.58 (m, 1H), 3.39-3.45 (m, 1H), 1.98-2.12 (m, 3H), 1.84-1.87 
(m, 1H). MS (ESI) 396.1 [M+Na]+. IR(cm-1) 1743 (C=O). The yellow solid (1.5 g, 4 
mmol) was dissolved in MeOH (50 mL) and 1.0 N NaOH (90 mL) was added and the 
mixture was stirred at RT for 16 h followed by 2 h of refluxing. The mixture was 
adjusted to pH 2 with 2.0 N HCl and extracted with EtOAc. The extract was washed 
with brine, dried (MgSO4), concentrated and purified by recrystallization from 
CH2Cl2/hexane to give 33 as an orange solid in 87.3% yield. m.p. 174-177 ºC. 1H 
NMR (CDCl3) δ 8.05 (s, 4H), 7.96-7.99 (m, 2H), 7.55-7.57 (m, 3H), 4.63 (br, 1H), 
3.58 (s, 1H), 3.35-3.40 (m, 1H), 1.83-2.18 (m, 4H). MS (ESI) 358.0 [M-H]-. IR (cm-1) 
1730 (acid), 2883 (br, COOH). 
 
 (1S)-N-((S)-4-Methyl-1-oxopentan-2-yl)-2-(4-(phenyldiazenyl)phenylsulfo- 
nyl)cyclopentane-carboxamide (16). CDI (474 mg, 2.93 mmol) was added to an 
ice-cooled solution of 33 (955 g, 2.66 mmol) in a mixture of THF (20 mL) and 
CH2Cl2 (15 mL) and stirred for 30 min. at RT. L-Leucinol was added and the mixture 
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was stirred at RT for 70 h after which the solvent was removed and the residue was 
recrystallized from CH2Cl2/hexane to give (1S)-N-((S)-1-hydroxy-4- 
methylpentan-2-yl)-2-(4-(phenyldiazenyl)phenylsulfonyl)cyclopentane carboxamide 
as orange solid in 60.0% yield. m.p. 152-154 ºC. 1H NMR (CDCl3) δ 7.97-8.10 (m, 
6H), 7.55-7.59 (m, 3H), 6.75 (d, J=9.0, 1H), 4.08-4.16 (m, 1H), 4.03 (dd, J=3.6, 8.4, 
1H), 3.81 (dd, J=3.6, 11.4, 1H), 3.67-3.73 (m, 1H), 3.55 (dd, J=5.4, 11.4, 1H), 
3.21-3.29 (m, 1H), 1.65-1.88 (m, 5H), 1.39-1.65 (m, 2H), 0.97 (t, J=6.3, 6H). MS 
(ESI) 481.2 [M+Na]+. IR (cm-1) 1636 (C=O), 3376 (amide). Dess-Martin oxidation 
(general procedure 3) of the orange solid (557 mg, 1.21 mmol) followed by column 
chromatographic purification (ethyl acetate/hexane, 2:1) of the crude product gave 16 
as yellow solid in 50.4% yield. m.p. 79-82 ºC. 1H NMR (CDCl3) δ 9.63 (s, 1H), 
7.98-8.13 (m, 6H), 7.57-7.60 (m, 3H), 7.26 (s, 1H), 4.43-4.50 (m, 1H), 4.22-4.25 (m, 
1H), 3.61-3.68 (m, 1H), 3.25-3.34 (m, 1H), 2.24-2.30 (m, 1H), 2.24-2.30 (m, 1H), 
1.66-1.86 (m, 6H), 1.01 (dd, J=6.0, 8.1, 6H). MS (ESI) 511.3 [M+MeOH+Na]+. 
IR(cm-1) 1655 (C=O), 1735 (CHO), 3366 (amide). Anal. Calcd. for: 
C23H28N4O4S•0.5H2O, C, 59.34; H, 6.28; N, 12.03; S, 6.89. Found: C, 59.28; H, 6.16; 
N, 11.96; S, 6.69. 
 
 
4.2.6 Synthesis of Compounds 18 and 19 
 
 (S)-(E)-Methyl 3-methyl-2-(4-styrylphenylsulfonamido)butanoate (39). 
Bromobenzene (12.2 mL, 116 mmol), Pd(OAc)2 (387 mg, 1.74 mmol), TEA (17 mL), 
and (o-Tol)3P (1.06 g, 3.5 mmol) were added to a solution of p-styrene sulfonic acid 
sodium salt (20 g, 97 mmol) in DMF (200 mL)/ H2O (4 mL) mixture. The mixture 
was stirred at 100 ºC for 2 h. After cooling to RT, a gray solid (21.9 g, 80%) separated 
out and was recovered by filtration, dried, and used in the next step without further 
purification. The solid was dissolved in (87 mL)/anhydrous DMF (4.5 mL) mixture 
and refluxed at 90 ºC for 3h. The solvent was removed in vacuo and the residue was 
dissolved in EtOAc (150 mL) and washed successively with 2.0 N HCl, saturated 
NaHCO3, brine, and dried (MgSO4). The EtOAc layer was recovered and 
concentrated under vacuum to give a gray solid (20.19 g, 93.3%), which was used 
without further purification. The solid (5g, 17.95 mmol) was mixed with L-Val-OMe 
hydrochloride (3.6 g, 21.47 mmol) and DIPEA (4 mL) in pyridine (25 mL) and the 
mixture was stirred for 4 days at RT, poured into 2.0 N HCl and extracted with EtOAc. 
The extract was washed twice with aqueous 1 N HCl, saturated aqueous NaHCO3, 
brine, and dried (MgSO4). The solvent was concentrated in vacuo and the residue was 
purified by column chromatography (acetone/hexane, 1:1) to give a white solid in 
45% yield. m.p. 173-175 ºC. 1H NMR (DMSO-d6) δ 8.26 (d, J=9.3), 7.639-7.800 (m, 
6H), 7.295-7.472 (m, 5H), 3.559 (dd, J=7.2, 9.0, 1H), 3.359 (s, 3H), 1.870-1.938 (m, 
1H), 0.820 (dd, J=6.9, 9.0, 6H). MS (ESI) 372.0 [M-H]-, 396.1 [M+Na]+. IR (cm-1) 
1735 (ester), 3278 (NH). 
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 (S)-(E)-3-Methyl-2-(4-styrylphenylsulfonamido)butanoic acid (40). NaOH 
(4.0 N, 40 mL) was added to a solution of 39 (6.85 g, 18.4 mmol) in MeOH (40 mL) 
and acetone (40 mL) mixture and stirred for 16 h at 48 ºC followed by adjustment of 
the pH to 2 with 2.0 N HCl and extraction of the solid that separated out with EtOAc. 
The extract was washed with brine, dried (MgSO4), filtered, and concentrated. The 
residue was purified by recrystallization from acetone/hexane to give a yellow solid 
80% yield. m.p. 193-195 ºC. 1H NMR (DMSO-d6) δ 12.58 (s, 1H), 8.01 (d, J=9.7), 
7.75 (s, 4H), 7.65 (d, J=7.2, 2H), 7.29-7.46 (m, 5H), 3.54 (dd, J=6.0, 9.0, 1H), 
1.90-1.97 (m, 1H), 0.81 (dd, J=6.9, 9.6, 6H). MS (ESI) 358.0 [M-H]-. IR (cm-1) 1747 
(C=O), 3313 (w, COOH). 
 
 (S)-N-((S)-1-Hydroxy-4-methylpentan-2-yl)-3-methyl-2-(4-styrylphenylsul-
fonamido)-butanamide (41). L-Leucinol (2.51 mL, 19.2 mmol) and TEA (4.53 mL, 
32.5 mmol) were added to a solution of 40 (5.3 g, 14.76 mmol) in anhydrous DMF 
(150 mL) at 0 ºC followed by the addition of Mukayaima’s reagent (4.53 g, 17.7 
mmol). After stirring for 4 days at RT, the solution was poured into H2O (1.5 L) to 
give the crude product, which was purified by recrystallization from ethyl acetate to 
obtain a white solid in 47% yield. m.p. 196-197 ºC. 1H NMR (DMSO-d6) δ 7.62-7.79 
(m, 7H), 7.54 (d, J=8.7, 1H), 7.28-7.43 (m, 5H), 4.55 (s, 1H), 3.48-3.56 (m, 1H), 
3.04-3.19 (m, 2H), 1.80-1.86 (m, 1H), 1.10-1.18 (m, 2H), 0.99-1.04 (m, 1H), 
0.63-0.86 (m, 12H). MS (ESI) 457.0 [M-H]-, 481.3 [M+Na]+. IR (cm-1) 1638 (C=O), 
3282 (sulfamide), 3205 (amide), 3503 (br, OH). 
 
 (S)-3-Methyl-N-((S)-4-methyl-1-oxopentan-2-yl)-2-(4-styrylphenylsulfona- 
mido)butanamide (18). Oxidation of 41 (2.58 g, 5.63 mmol) with PySO3 complex 
(general procedure 4) followed by recrystallization of the crude product from ethyl 
acetate/hexane gave 18 as a white solid in 85% yield. m.p. 174-175 ºC. 1H NMR 
(DMSO-d6) δ 9.51 (s, 1H), 7.85 (d, J=8.5, 2H), 7.62 (d, J=8.5, 2H), 7.42 (t, J= 8.0, 
2H), 7.35 (t, J=7.5, 1H), 7.25 (d, J=16.5, 1H), 7.10 (d, J=16.5, 1H), 6.12 (d, J=7.5,1H), 
5.34 (d, J=8.5, 1H), 4.41-4.45 (m, 1H), 3.62 (dd, J=5.0, 8.0, 1H), 2.10-2.17 (m, 1H), 
1.54-1.58 (m, 1H), 1.41-1.49 (m, 1H), 1.26-1.32 (m, 1H), 0.96 (d, J=6.5, 3H), 
0.85-0.90 (m, 9H). MS (ESI) 374.0 [M-H]-, 398 [M+Na]+. IR (cm-1) 1637 (C=O), 
1728 (CHO). Anal. Calcd. for: C25H32N2O4S, C, 65.76; H, 7.06; N, 6.14; S, 7.02.  
Found: C, 65.51; H, 7.10; N, 6.13; S, 7.24. 
 
 (2S)-N-((2S)-1-Cyano-1-hydroxy-4-methylpentan-2-yl)-3-methyl-2-(4-styr- 
ylphenyl-sulfonamido)butanamide (42). NaHSO3 (3.2%, 14mL) was added to a 
solution of 18 (2 g, 4.38 mmol) in MeOH (30 mL) and stirred at RT for 40 h followed 
by the addition of 3.2% KCN solution (10 mL) and EtOAc (50 mL). After stirring for 
another 5 h, the mixture was extracted with EtOAc (3 x 50mL). The extract was 
concentrated and the residue was purified by recrystallization from acetone/hexane to 
give 19 as a white solid in 90% yield. m.p. 125-128 ºC. 1H NMR (CDCl3) δ 7.09-7.88 
(m, 11H), 6.53-6.69 (m, 1H), 5.33-5.40 (m, 1H), 4.51-4.59 (m, 1H), 4.10-4.27 (m, 
1H), 3.50-3.61 (m, 1H), 2.15-2.25 (m, 1H), 1.43-1.62 (m, 3H), 0.81-0.98 (m, 12H). 
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MS (ESI) 374.0 [M-H]-, 398 [M+Na]+. IR (cm-1) 1736 (ester), 3282 (amide). 
 
 (3S)-Methyl-2-hydroxy-5-methyl-3-((S)-3-methyl-2-(4-styrylphenylsulfon- 
amido)-butanamido) hexanoate (43). Compound 42 (932 mg, 19.4 mmol) was 
dissolved in MeOH (40 mL) containing conc. HCl (11 mL) and the mixture was 
stirred for 24 h at 54 ºC. The solvent was removed in vacuo and the residue was 
purified by column chromatography (acetone/hexane, 1:1) to give 43 as a white solid 
in 75.2% yield. m.p. 180-183 ºC. 1H NMR (DMSO-d6) δ 7.28-7.73 (m, 13H), 
5.35-5.58 (m, 1H), 3.83-3.97 (m, 2H), 3.58-3.68 (m, 1H), 1.79-1.83 (m, 1H), 
1.01-1.27 (m, 3H), 0.55-0.91 (m, 12H). MS (ESI) 374.0 [M-H]-, 398 [M+Na]+. IR 
(cm-1) 1736 (ester), 3282 (amide). 
 
 (3S)-2-Hydroxy-5-methyl-3-((S)-3-methyl-2-(4-styrylphenylsulfonamido) 
butanamido)-hexanamide (44). A solution of 43 (750 mg, 1.4 mmol) in 7.0 N 
methanolic ammonia (30 mL) was stirred at RT for 96 h and the mixture was 
concentrated to give a residue, which was purified by column chromatography 
(acetone/hexane, 2:1) to obtain 44 as a white solid in 64% yield. m.p. 234-242 ºC. 1H 
NMR (DMSO-d6) δ 7.04-7.77 (m, 15H), 5.49-5.54(m, 1H), 3.96-4.03 (m, 1H), 
3.58-3.71 (m, 2H), 1.84-1.93 (m, 1H), 1.24-1.34 (m, 1H), 1.03-1.15 (m, 2H), 
0.53-0.87 (m, 12H). MS (ESI) 500.0 [M-H]-. IR (cm-1) 1660, 1643 (C=O), 3326 
(OH). 
 
 (S)-5-Methyl-3-((S)-3-methyl-2-(4-styrylphenylsulfonamido)butanamido)- 
2-oxohexanamide (19). Oxidation of 44 (400 mg, 0.798 mmol) with pyridine-sulfur 
trioxide complex (general procedure 4) followed by flash chromatographic 
purification (acetone/hexane, 1:1) of the crude product gave 19 as a white solid in 
52.7% yield. m.p. 209-211 ºC. 1H NMR (DMSO-d6) δ 8.12 (d, J=6.9, 1H), 7.97 (s, 
1H), 7.63-7,77 (m, 8H), 7.29-7.45 (m, 5H), 4.79 (t, J=7.2, 1H), 3.62 (dd, J=6.6, 9.3, 
1H), 1.81-1.88 (m, 1H), 1.14-1.33 (m, 3H), 0.63-0.89 (m, 12H). MS (ESI) 
498.0[M-H]-, 554.3 [M+MeOH+Na]+. IR (cm-1) 1637 (C=O), 1693 (C=O), 1740 
(C=O) 3124, 3276, 3359, 3463 (amide). Anal. Calcd. for: C26H33N3O5S•0.2H2O, C, 
62.06; H, 6.69; N, 8.35; S, 6.37.  Found: C, 62.01; H, 6.59; N, 8.33; S, 6.27. 
 
 
4.3 Determination of the Antiproliferative Activity of the Calpain Inhibitors  
 
 
4.3.1 Cell Cultures 
  
 Cell lines were cultured in a Dulbecco’s modified Eagle’s Medium (DMEM, 
Cellgro Mediatech, Inc.), supplemented with 5% (v/v) fetal bovine serum (FBS, 
Atlanta Biologics, Inc.), 1% (v/v) antibiotic/antimycotic solution (Sigma), and 0.05% 
bovine insulin (25mM, pH 8.2, Sigma) for human A375 melanoma cells and mouse 
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B16F1 melanoma cells. Cell cultures were maintained at 37 oC in a humidified 
atmosphere which contained 5% CO2.  
 
 
4.3.2 Cell Death Assay and GI50 Value Determination in Melanoma Cells.  
 
 During the initial screen, compounds dissolved in DMSO were added to the 
plates to give a 20 µM solution followed by sulforhodamine B (SRB). To determine 
GI50 values, human melanoma cell line A375 and mouse melanoma cell line B16F1 
were trypsinized and harvested by centrifugation for 3 minutes. Cells were then 
resuspended in the same media (5% FBS, 1% antibiotic and 0.05% insulin in DMEM) 
and counted using a hemocytometer. Cells were seeded into U-bottom 96-well 
microtiter plate at 5000 cells/well. After 12 h, media were changed and 8 dilutions of 
compounds were added. Cells were incubated with each compound for 48 h. Positive 
controls were performed with taxol. Negative controls were performed with cells 
incubated with media only.  
 
 Cell death was quantitated by sulforhodamine B (SRB) assay according to the 
manufacturer's protocol (Sigma-Aldrich).172 Cells were fixed with 10% TCA, washed 
five times with tap water, and incubated with 0.4% sulforhodamine B in 1% acetic acid 
solution for 30 min at RT. 10 mM solution of Tris Base (Fluka) was added to release 
the dye from the cells for 1 h and the absorbance was measured at 490 nm in EL800 
Absorbance Microplate reader (Biotek). 
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